# Content

```
┌─────────────────────────────────────────────┐
│ Invited                          N=50 457    │
│                                              │
│  -  SARS-Cov-2 PCR positive between 1st Oct. │
│     2020 and 1st Apr. 2021                   │
│  -  Living in the administrative district of │
│     cooperating public health authorities    │
│  -  18 to 65 years old at the 1st Aug. 2021  │
└─────────────────────────────────────────────┘
        │
        │      ┌──────────────────────────────┐
        ├─────▶│ Undeliverable      N=2794    │
        │      └──────────────────────────────┘
        ▼
┌─────────────────────────────────────────────┐
│ Responded                        N=12 053    │
└─────────────────────────────────────────────┘
        │
        │      ┌──────────────────────────────┐
        │      │ Excluded            N=343    │
        │      │                              │
        ├─────▶│  -   4   non-binary sex      │
        │      │  -  29   unknown sex         │
        │      │  -  310  unknown age         │
        │      └──────────────────────────────┘
        ▼
┌─────────────────────────────────────────────┐
│ Analytic cohort                  N=11 710    │
└─────────────────────────────────────────────┘
```

**Figure A. Flow chart for the inclusion of SARS-CoV-2 PCR-positive subjects (tested between 1st October 2020 and 1st April 2021) aged 18-65 years from defined regions in southern Germany.**

**Left column**

| Symptom | N | Prevalence (%) (pre / during / current) | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| Hair loss | 10946 | 9.8 (9.3 to 10.4) / 11.8 (11.2 to 12.4) / 14.2 (13.5 to 14.9) | 1.45 (1.38 to 1.52) / 4.4 (3.8 to 5.0) |
| Headache | 10979 | 20.8 (20.0 to 21.5) / 65.5 (64.6 to 66.4) / 28.6 (27.7 to 29.4) | 1.37 (1.33 to 1.42) / 7.8 (7.0 to 8.5) |
| Confusion | 11155 | 0.6 (0.5 to 0.8) / 11.1 (10.6 to 11.7) / 6.8 (6.4 to 7.3) | 10.60 (8.45 to 13.29) / 6.2 (5.7 to 6.7) |
| Concentration difficulties | 11179 | 5.5 (5.1 to 5.9) / 41.3 (40.4 to 42.2) / 31.5 (30.6 to 32.3) | 5.77 (5.35 to 6.21) / 26.0 (25.2 to 26.8) |
| Memory disturbance | 11174 | 3.6 (3.3 to 4.0) / 23.0 (22.2 to 23.8) / 25.0 (24.2 to 25.8) | 6.92 (6.31 to 7.58) / 21.4 (20.6 to 22.2) |
| Anxiety | 11174 | 5.4 (5.0 to 5.8) / 15.6 (14.9 to 16.3) / 10.7 (10.1 to 11.2) | 1.98 (1.86 to 2.12) / 5.3 (4.8 to 5.8) |
| Depressive mood | 11149 | 11.7 (11.1 to 12.3) / 21.6 (20.8 to 22.3) / 20.4 (19.6 to 21.1) | 1.74 (1.66 to 1.81) / 8.6 (8.0 to 9.3) |
| Dizziness | 11118 | 6.7 (6.2 to 7.2) / 33.9 (33.0 to 34.8) / 18.0 (17.3 to 18.7) | 2.69 (2.52 to 2.87) / 11.3 (10.6 to 12.0) |
| Altered smell | 11167 | 1.7 (1.5 to 2.0) / 57.3 (56.3 to 58.2) / 22.5 (21.7 to 23.2) | 12.86 (11.20 to 14.77) / 20.7 (19.9 to 21.5) |
| Altered taste | 11134 | 1.2 (1.0 to 1.4) / 57.3 (56.4 to 58.2) / 17.5 (16.8 to 18.2) | 14.62 (12.34 to 17.32) / 16.3 (15.6 to 17.0) |
| Cough | 11130 | 6.0 (5.6 to 6.5) / 57.5 (56.6 to 58.4) / 12.9 (12.3 to 13.5) | 2.14 (2.00 to 2.29) / 6.8 (6.3 to 7.4) |
| Hoarseness | 11148 | 2.9 (2.6 to 3.2) / 28.2 (27.3 to 29.0) / 7.1 (6.6 to 7.6) | 2.46 (2.22 to 2.73) / 4.2 (3.7 to 4.7) |
| Sore throat | 11208 | 4.5 (4.1 to 4.9) / 56.4 (55.5 to 57.4) / 8.7 (8.2 to 9.3) | 1.96 (1.79 to 2.13) / 4.3 (3.7 to 4.8) |
| Wheezing | 11182 | 2.8 (2.5 to 3.1) / 24.4 (23.6 to 25.2) / 9.4 (8.9 to 10.0) | 3.39 (3.07 to 3.75) / 6.7 (6.2 to 7.2) |
| Shortness of breath | 11183 | 4.9 (4.5 to 5.3) / 54.1 (53.2 to 55.0) / 30.8 (30.0 to 31.7) | 6.33 (5.85 to 6.86) / 26.0 (25.1 to 26.8) |

Legend: ■ pre ■ during ■ current

**Right column**

| Symptom | N | Prevalence (%) (pre / during / current) | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| Chest pain | 11262 | 1.7 (1.5 to 2.0) / 26.1 (25.3 to 26.9) / 10.3 (9.8 to 10.9) | 5.98 (5.23 to 6.84) / 8.6 (8.0 to 9.1) |
| Vomiting | 11282 | 0.5 (0.4 to 0.6) / 4.7 (4.3 to 5.1) / 0.8 (0.6 to 1.0) | 1.57 (1.18 to 2.09) / 0.3 (0.1 to 0.5) |
| Nausea | 11280 | 1.6 (1.4 to 1.9) / 18.3 (17.6 to 19.0) / 4.3 (4.0 to 4.7) | 2.68 (2.33 to 3.09) / 2.7 (2.3 to 3.1) |
| Abdominal pain | 11262 | 3.3 (2.9 to 3.6) / 12.8 (12.2 to 13.5) / 5.5 (5.1 to 5.9) | 1.68 (1.54 to 1.84) / 2.2 (1.9 to 2.6) |
| Diarrhea | 11270 | 4.1 (3.8 to 4.5) / 21.2 (20.5 to 22.0) / 7.0 (6.5 to 7.5) | 1.69 (1.57 to 1.82) / 2.9 (2.5 to 3.2) |
| Chills | 11238 | 0.9 (0.8 to 1.1) / 40.7 (39.8 to 41.6) / 2.0 (1.8 to 2.3) | 2.12 (1.72 to 2.62) / 1.1 (0.8 to 1.3) |
| Fever | 11217 | 0.9 (0.7 to 1.1) / 52.5 (51.5 to 53.4) / 1.2 (1.0 to 1.4) | 1.36 (1.07 to 1.72) / 0.3 (0.1 to 0.6) |
| Melalgia | 11190 | 3.5 (3.2 to 3.8) / 67.5 (66.7 to 68.4) / 11.7 (11.1 to 12.3) | 3.36 (3.06 to 3.69) / 8.2 (7.7 to 8.8) |
| Myalgia | 11221 | 4.3 (4.0 to 4.7) / 49.3 (48.4 to 50.2) / 14.3 (13.6 to 14.9) | 3.29 (3.04 to 3.57) / 9.9 (9.3 to 10.5) |
| Arthralgia | 11192 | 9.1 (8.6 to 9.7) / 42.5 (41.6 to 43.5) / 18.4 (17.7 to 19.1) | 2.02 (1.92 to 2.12) / 9.3 (8.7 to 9.9) |
| Paresthesia | 11236 | 4.3 (3.9 to 4.7) / 17.4 (16.7 to 18.1) / 11.9 (11.3 to 12.5) | 2.78 (2.58 to 3.00) / 7.6 (7.1 to 8.1) |
| Sleep disorder | 11255 | 15.1 (14.4 to 15.8) / 33.5 (32.6 to 34.4) / 26.4 (25.6 to 27.2) | 1.75 (1.69 to 1.81) / 11.3 (10.6 to 12.0) |
| Chronic fatigue | 11210 | 4.9 (4.5 to 5.3) / 44.2 (43.3 to 45.1) / 27.1 (26.2 to 27.9) | 5.55 (5.14 to 6.01) / 22.2 (21.4 to 23.0) |
| Rapid physical exhaustion | 11175 | 4.0 (3.6 to 4.3) / 66.7 (65.8 to 67.6) / 36.2 (35.3 to 37.1) | 9.12 (8.34 to 9.98) / 32.2 (31.3 to 33.1) |
| Skin rash | 11248 | 3.3 (3.0 to 3.7) / 7.0 (6.6 to 7.5) / 5.6 (5.2 to 6.0) | 1.67 (1.53 to 1.82) / 2.2 (1.9 to 2.6) |

Legend: ■ pre ■ during ■ current

**Figure B. Prevalence of symptoms in percent (%) before (pre), during, and 6-12 months after (current) the SARS-CoV-2 index infection including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals.**

**Hair loss — Men**

| Age | N | Prevalence (%) pre / during / current | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 881 | 6.7 (5.2 to 8.6) / 6.9 (5.4 to 8.8) / 7.7 (6.1 to 9.7) | 1.15 (0.99 to 1.35) / 1.0 (−0.1 to 2.1) |
| 30–<40 | 832 | 9.5 (7.7 to 11.7) / 7.9 (6.3 to 10.0) / 8.5 (6.8 to 10.7) | 0.90 (0.76 to 1.06) / −1.0 (−2.4 to 0.5) |
| 40–<50 | 786 | 10.8 (8.8 to 13.2) / 7.4 (5.8 to 9.5) / 8.3 (6.6 to 10.4) | 0.76 (0.63 to 0.93) / −2.5 (−4.4 to −0.7) |
| 50–<60 | 1303 | 8.1 (6.8 to 9.8) / 5.8 (4.7 to 7.3) / 5.6 (4.5 to 7.0) | 0.69 (0.57 to 0.84) / −2.5 (−3.8 to −1.2) |
| 60–65 | 702 | 6.7 (5.1 to 8.8) / 5.6 (4.1 to 7.5) / 5.0 (3.6 to 6.9) | 0.74 (0.53 to 1.04) / −1.7 (−3.6 to 0.2) |

pre · during · current

**Hair loss — Women**

| Age | N | Prevalence (%) pre / during / current | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1506 | 12.3 (10.7 to 14.1) / 14.4 (12.7 to 16.3) / 17.8 (16.0 to 19.8) | 1.45 (1.30 to 1.62) / 5.5 (3.9 to 7.1) |
| 30–<40 | 1208 | 12.7 (11.0 to 14.8) / 15.0 (13.1 to 17.1) / 20.1 (18.0 to 22.5) | 1.58 (1.39 to 1.80) / 7.4 (5.3 to 9.4) |
| 40–<50 | 1153 | 11.5 (9.8 to 13.5) / 15.9 (13.9 to 18.1) / 21.2 (18.9 to 23.7) | 1.83 (1.61 to 2.09) / 9.6 (7.6 to 11.6) |
| 50–<60 | 1859 | 9.3 (8.0 to 10.7) / 15.5 (14.0 to 17.3) / 19.5 (17.8 to 21.4) | 2.11 (1.86 to 2.40) / 10.3 (8.6 to 11.9) |
| 60–65 | 716 | 7.5 (5.8 to 9.7) / 16.3 (13.8 to 19.3) / 17.2 (14.6 to 20.2) | 2.28 (1.83 to 2.83) / 9.6 (7.3 to 12.0) |

pre · during · current

**Headache — Men**

| Age | N | Prevalence (%) pre / during / current | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 876 | 13.0 (11.0 to 15.4) / 60.6 (57.5 to 63.9) / 16.2 (13.9 to 18.8) | 1.25 (1.08 to 1.43) / 3.2 (1.2 to 5.2) |
| 30–<40 | 838 | 12.4 (10.4 to 14.9) / 59.7 (56.4 to 63.1) / 18.3 (15.8 to 21.1) | 1.47 (1.27 to 1.71) / 5.8 (3.7 to 8.0) |
| 40–<50 | 791 | 10.6 (8.7 to 13.0) / 59.0 (55.7 to 62.6) / 21.2 (18.6 to 24.3) | 2.00 (1.66 to 2.41) / 10.6 (7.9 to 13.3) |
| 50–<60 | 1317 | 11.5 (9.9 to 13.3) / 55.8 (53.2 to 58.6) / 19.5 (17.5 to 21.8) | 1.70 (1.49 to 1.94) / 8.0 (6.1 to 10.0) |
| 60–65 | 709 | 10.6 (8.5 to 13.1) / 50.1 (46.5 to 53.9) / 18.2 (15.6 to 21.3) | 1.72 (1.41 to 2.09) / 7.6 (5.0 to 10.3) |

pre · during · current

**Headache — Women**

| Age | N | Prevalence (%) pre / during / current | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1518 | 31.6 (29.3 to 34.0) / 75.0 (72.9 to 77.2) / 37.4 (35.1 to 39.9) | 1.19 (1.12 to 1.26) / 5.9 (3.8 to 7.9) |
| 30–<40 | 1220 | 30.3 (27.9 to 33.0) / 73.2 (70.8 to 75.7) / 36.1 (33.5 to 38.9) | 1.19 (1.10 to 1.28) / 5.7 (3.3 to 8.2) |
| 40–<50 | 1158 | 29.3 (26.8 to 32.0) / 72.5 (69.9 to 75.1) / 39.7 (37.0 to 42.6) | 1.36 (1.26 to 1.46) / 10.4 (8.0 to 12.9) |
| 50–<60 | 1852 | 25.0 (23.1 to 27.1) / 70.5 (68.5 to 72.6) / 33.9 (31.8 to 36.1) | 1.35 (1.26 to 1.45) / 8.9 (6.9 to 10.8) |
| 60–65 | 700 | 14.6 (12.2 to 17.4) / 60.4 (56.9 to 64.2) / 27.3 (24.2 to 30.8) | 1.87 (1.59 to 2.21) / 12.7 (9.6 to 15.9) |

pre · during · current

**Confusion — Men**

| Age | N | Prevalence (%) pre / during / current | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 893 | 0.6 (0.2 to 1.3) / 9.2 (7.5 to 11.3) / 4.3 (3.1 to 5.8) | 7.60 (3.20 to 18.05) / 3.7 (2.4 to 5.0) |
| 30–<40 | 848 | 0.9 (0.5 to 1.9) / 9.7 (7.9 to 11.9) / 5.2 (3.9 to 6.9) | 5.50 (2.84 to 10.65) / 4.2 (2.8 to 5.7) |
| 40–<50 | 813 | 0.1 (0.0 to 0.9) / 10.2 (8.3 to 12.5) / 6.9 (5.3 to 8.9) | 56.00 (7.75 to 404.50) / 6.8 (5.0 to 8.5) |
| 50–<60 | 1337 | 0.8 (0.5 to 1.5) / 12.6 (10.9 to 14.5) / 7.8 (6.5 to 9.4) | 9.45 (5.31 to 16.83) / 7.0 (5.5 to 8.4) |
| 60–65 | 719 | 0.6 (0.2 to 1.5) / 11.1 (9.0 to 13.7) / 5.8 (4.4 to 7.8) | 10.50 (4.13 to 26.67) / 5.3 (3.6 to 6.9) |

pre · during · current

**Confusion — Women**

| Age | N | Prevalence (%) pre / during / current | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1520 | 1.0 (0.6 to 1.6) / 11.7 (10.2 to 13.4) / 7.0 (5.9 to 8.5) | 7.13 (4.37 to 11.63) / 6.1 (4.8 to 7.3) |
| 30–<40 | 1233 | 0.7 (0.4 to 1.4) / 11.3 (9.6 to 13.2) / 6.2 (5.0 to 7.8) | 8.56 (4.51 to 16.23) / 5.5 (4.2 to 6.8) |
| 40–<50 | 1171 | 0.3 (0.1 to 0.9) / 11.6 (9.9 to 13.6) / 8.9 (7.4 to 10.7) | 26.00 (9.85 to 68.62) / 8.5 (6.9 to 10.2) |
| 50–<60 | 1906 | 0.6 (0.4 to 1.1) / 11.9 (10.5 to 13.4) / 7.8 (6.7 to 9.1) | 12.33 (7.06 to 21.55) / 7.1 (5.9 to 8.3) |
| 60–65 | 715 | 0.4 (0.1 to 1.3) / 9.7 (7.7 to 12.1) / 6.0 (4.5 to 8.0) | 14.33 (4.56 to 45.03) / 5.6 (3.8 to 7.4) |

pre · during · current

**Figure C. Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. N represents the number of respondents in the respective age strata.**

## Concentration difficulties — Men

| Age | N | Prevalence (%) pre / during / current | Current vs. pre — Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 885 | 5.5 (4.2 to 7.3); 32.8 (29.8 to 36.0); 18.4 (16.0 to 21.2) | 3.33 (2.59 to 4.27); 12.9 (10.5 to 15.3) |
| 30–<40 | 854 | 4.9 (3.7 to 6.6); 33.6 (30.6 to 36.9); 20.6 (18.1 to 23.5) | 4.19 (3.17 to 5.54); 15.7 (13.1 to 18.3) |
| 40–<50 | 809 | 2.5 (1.6 to 3.8); 38.7 (35.5 to 42.2); 26.6 (23.7 to 29.8) | 10.75 (7.01 to 16.49); 24.1 (21.1 to 27.1) |
| 50–<60 | 1337 | 4.5 (3.5 to 5.7); 40.5 (37.9 to 43.2); 30.4 (28.0 to 32.9) | 6.77 (5.33 to 8.59); 25.9 (23.5 to 28.3) |
| 60–65 | 721 | 5.1 (3.7 to 7.0); 40.2 (36.8 to 44.0); 31.2 (28.0 to 34.8) | 6.08 (4.49 to 8.24); 26.1 (22.7 to 29.4) |

legend: pre / during / current

## Concentration difficulties — Women

| Age | N | Prevalence (%) pre / during / current | Current vs. pre — Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1525 | 7.2 (6.0 to 8.6); 43.8 (41.4 to 46.4); 29.2 (27.0 to 31.6) | 4.05 (3.42 to 4.79); 22.0 (19.8 to 24.2) |
| 30–<40 | 1234 | 6.0 (4.8 to 7.5); 41.1 (38.4 to 43.9); 30.5 (28.0 to 33.1) | 5.08 (4.11 to 6.28); 24.5 (22.0 to 27.0) |
| 40–<50 | 1178 | 5.2 (4.1 to 6.6); 44.0 (41.2 to 46.9); 37.9 (35.3 to 40.8) | 7.33 (5.78 to 9.29); 32.8 (30.0 to 35.5) |
| 50–<60 | 1915 | 5.8 (4.9 to 7.0); 45.4 (43.3 to 47.7); 41.0 (38.8 to 43.3) | 7.01 (5.89 to 8.35); 35.1 (32.9 to 37.3) |
| 60–65 | 721 | 6.2 (4.7 to 8.3); 45.5 (42.0 to 49.3); 38.7 (35.3 to 42.4) | 6.20 (4.73 to 8.13); 32.5 (29.0 to 35.9) |

legend: pre / during / current

## Memory disturbance — Men

| Age | N | Prevalence (%) pre / during / current | Current vs. pre — Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 890 | 2.6 (1.7 to 3.9); 11.5 (9.5 to 13.8); 10.4 (8.6 to 12.7) | 4.04 (2.81 to 5.82); 7.9 (6.0 to 9.7) |
| 30–<40 | 847 | 2.1 (1.3 to 3.4); 14.4 (12.2 to 17.0); 14.4 (12.2 to 17.0) | 6.78 (4.39 to 10.47); 12.3 (10.0 to 14.5) |
| 40–<50 | 808 | 1.5 (0.8 to 2.6); 21.7 (19.0 to 24.7); 22.9 (20.2 to 26.0) | 15.42 (8.81 to 26.98); 21.4 (18.5 to 24.3) |
| 50–<60 | 1339 | 4.9 (3.8 to 6.2); 26.4 (24.1 to 28.8); 27.7 (25.4 to 30.2) | 5.71 (4.56 to 7.14); 22.9 (20.6 to 25.1) |
| 60–65 | 716 | 5.2 (3.8 to 7.1); 23.7 (20.8 to 27.1); 25.4 (22.4 to 28.8) | 4.92 (3.66 to 6.61); 20.3 (17.2 to 23.3) |

legend: pre / during / current

## Memory disturbance — Women

| Age | N | Prevalence (%) pre / during / current | Current vs. pre — Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1528 | 2.6 (1.9 to 3.5); 17.4 (15.6 to 19.4); 18.2 (16.4 to 20.2) | 7.13 (5.29 to 9.60); 15.6 (13.8 to 17.5) |
| 30–<40 | 1232 | 3.4 (2.5 to 4.6); 20.9 (18.7 to 23.3); 22.9 (20.7 to 25.4) | 6.71 (5.06 to 8.92); 19.5 (17.2 to 21.7) |
| 40–<50 | 1183 | 3.0 (2.2 to 4.2); 26.8 (24.4 to 29.4); 31.4 (28.8 to 34.1) | 10.31 (7.55 to 14.07); 28.3 (25.7 to 30.9) |
| 50–<60 | 1911 | 4.7 (3.8 to 5.8); 30.5 (28.5 to 32.6); 35.4 (33.3 to 37.6) | 7.52 (6.19 to 9.14); 30.7 (28.6 to 32.8) |
| 60–65 | 720 | 5.8 (4.3 to 7.8); 30.7 (27.5 to 34.3); 32.4 (29.1 to 36.0) | 5.55 (4.21 to 7.31); 26.5 (23.3 to 29.8) |

legend: pre / during / current

## Anxiety — Men

| Age | N | Prevalence (%) pre / during / current | Current vs. pre — Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 886 | 3.2 (2.2 to 4.6); 5.8 (4.4 to 7.5); 4.9 (3.6 to 6.5) | 1.54 (1.17 to 2.01); 1.7 (0.6 to 2.7) |
| 30–<40 | 848 | 3.5 (2.5 to 5.0); 8.5 (6.8 to 10.6); 6.3 (4.8 to 8.1) | 1.77 (1.33 to 2.34); 2.7 (1.4 to 4.0) |
| 40–<50 | 808 | 3.3 (2.3 to 4.8); 12.6 (10.5 to 15.1); 7.3 (5.7 to 9.3) | 2.19 (1.58 to 3.03); 4.0 (2.4 to 5.5) |
| 50–<60 | 1344 | 3.3 (2.5 to 4.5); 15.0 (13.2 to 17.0); 9.3 (7.9 to 11.0) | 2.78 (2.17 to 3.56); 6.0 (4.6 to 7.3) |
| 60–65 | 724 | 4.3 (3.0 to 6.0); 16.0 (13.6 to 18.9); 8.4 (6.6 to 10.7) | 1.97 (1.45 to 2.67); 4.1 (2.3 to 6.0) |

legend: pre / during / current

## Anxiety — Women

| Age | N | Prevalence (%) pre / during / current | Current vs. pre — Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1524 | 8.6 (7.3 to 10.1); 15.0 (13.3 to 16.9); 12.8 (11.2 to 14.6) | 1.49 (1.32 to 1.68); 4.2 (2.9 to 5.5) |
| 30–<40 | 1232 | 6.9 (5.6 to 8.5); 15.9 (14.0 to 18.1); 10.5 (8.9 to 12.3) | 1.52 (1.26 to 1.83); 3.6 (2.0 to 5.1) |
| 40–<50 | 1176 | 6.0 (4.8 to 7.6); 18.8 (16.7 to 21.2); 13.4 (11.6 to 15.5) | 2.23 (1.84 to 2.69); 7.4 (5.7 to 9.1) |
| 50–<60 | 1909 | 6.2 (5.2 to 7.4); 22.0 (20.2 to 23.9); 14.9 (13.4 to 16.6) | 2.39 (2.05 to 2.78); 8.6 (7.2 to 10.1) |
| 60–65 | 723 | 4.7 (3.4 to 6.5); 18.9 (16.3 to 22.0); 11.6 (9.5 to 14.2) | 2.47 (1.86 to 3.28); 6.9 (4.9 to 9.0) |

legend: pre / during / current

**Figure C. Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. N represents the number of respondents in the respective age strata. (…continued)**

**Figure C. Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. N represents the number of respondents in the respective age strata. (…continued)**

**Altered taste — Men**

| Age | N | Prevalence (%) | Current vs. pre — Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 886 | 0.7 (0.3 to 1.5) / 52.7 (49.5 to 56.1) / 12.4 (10.4 to 14.8) | 18.33 (8.24 to 40.81) / 11.7 (9.6 to 13.9) |
| 30–<40 | 845 | 1.1 (0.6 to 2.0) / 57.6 (54.4 to 61.1) / 15.1 (12.9 to 17.8) | 14.22 (7.34 to 27.54) / 14.1 (11.6 to 16.6) |
| 40–<50 | 798 | 1.3 (0.7 to 2.3) / 54.8 (51.4 to 58.3) / 15.7 (13.3 to 18.4) | 12.50 (6.73 to 23.23) / 14.4 (11.9 to 17.0) |
| 50–<60 | 1337 | 1.6 (1.0 to 2.4) / 50.4 (47.8 to 53.2) / 15.3 (13.5 to 17.4) | 9.76 (6.40 to 14.89) / 13.8 (11.8 to 15.7) |
| 60–65 | 721 | 0.6 (0.2 to 1.5) / 41.7 (38.3 to 45.5) / 13.2 (10.9 to 15.9) | 23.75 (8.91 to 63.28) / 12.6 (10.1 to 15.1) |

legend: pre · during · current

**Altered taste — Women**

| Age | N | Prevalence (%) | Current vs. pre — Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1519 | 0.8 (0.4 to 1.4) / 61.7 (59.3 to 64.2) / 17.5 (15.7 to 19.5) | 22.17 (12.62 to 38.95) / 16.7 (14.8 to 18.6) |
| 30–<40 | 1229 | 0.7 (0.3 to 1.3) / 65.5 (62.9 to 68.2) / 19.2 (17.1 to 21.5) | 29.50 (14.71 to 59.16) / 18.6 (16.3 to 20.8) |
| 40–<50 | 1171 | 1.2 (0.7 to 2.0) / 61.8 (59.1 to 64.7) / 19.9 (17.7 to 22.3) | 16.64 (9.86 to 28.10) / 18.7 (16.4 to 21.0) |
| 50–<60 | 1909 | 1.6 (1.1 to 2.2) / 60.9 (58.7 to 63.1) / 21.4 (19.7 to 23.3) | 13.63 (9.53 to 19.50) / 19.9 (18.0 to 21.7) |
| 60–65 | 719 | 2.6 (1.7 to 4.1) / 53.4 (49.9 to 57.2) / 19.2 (16.5 to 22.3) | 7.26 (4.70 to 11.22) / 16.6 (13.7 to 19.4) |

legend: pre · during · current

**Cough — Men**

| Age | N | Prevalence (%) | Current vs. pre — Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 884 | 4.4 (3.2 to 6.0) / 58.0 (54.9 to 61.4) / 6.6 (5.1 to 8.4) | 1.49 (1.11 to 1.98) / 2.1 (0.6 to 3.7) |
| 30–<40 | 847 | 5.1 (3.8 to 6.8) / 56.2 (53.0 to 59.6) / 9.4 (7.7 to 11.6) | 1.86 (1.42 to 2.45) / 4.4 (2.5 to 6.2) |
| 40–<50 | 790 | 6.3 (4.8 to 8.3) / 57.2 (53.9 to 60.8) / 12.5 (10.4 to 15.1) | 1.98 (1.53 to 2.56) / 6.2 (4.0 to 8.4) |
| 50–<60 | 1326 | 7.5 (6.2 to 9.1) / 55.8 (53.2 to 58.5) / 16.3 (14.4 to 18.4) | 2.16 (1.82 to 2.57) / 8.7 (6.9 to 10.6) |
| 60–65 | 719 | 9.2 (7.3 to 11.6) / 55.6 (52.1 to 59.4) / 18.6 (16.0 to 21.7) | 2.03 (1.65 to 2.50) / 9.5 (6.8 to 12.1) |

legend: pre · during · current

**Cough — Women**

| Age | N | Prevalence (%) | Current vs. pre — Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1532 | 3.7 (2.8 to 4.7) / 61.2 (58.8 to 63.7) / 8.4 (7.1 to 9.9) | 2.30 (1.80 to 2.94) / 4.8 (3.4 to 6.1) |
| 30–<40 | 1235 | 4.2 (3.2 to 5.5) / 56.3 (53.6 to 59.1) / 9.3 (7.8 to 11.1) | 2.21 (1.70 to 2.88) / 5.1 (3.5 to 6.7) |
| 40–<50 | 1177 | 5.4 (4.2 to 6.8) / 55.1 (52.4 to 58.1) / 12.4 (10.7 to 14.4) | 2.32 (1.83 to 2.93) / 7.1 (5.2 to 8.9) |
| 50–<60 | 1898 | 7.3 (6.2 to 8.5) / 59.4 (57.2 to 61.6) / 16.8 (15.2 to 18.6) | 2.31 (1.99 to 2.69) / 9.5 (7.9 to 11.1) |
| 60–65 | 722 | 8.7 (6.9 to 11.0) / 56.2 (52.7 to 60.0) / 18.8 (16.2 to 21.9) | 2.16 (1.74 to 2.68) / 10.1 (7.5 to 12.8) |

legend: pre · during · current

**Hoarseness — Men**

| Age | N | Prevalence (%) | Current vs. pre — Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 892 | 2.0 (1.3 to 3.2) / 25.6 (22.9 to 28.6) / 2.1 (1.4 to 3.3) | 1.06 (0.63 to 1.75) / 0.1 (−0.9 to 1.2) |
| 30–<40 | 845 | 1.3 (0.7 to 2.3) / 20.5 (17.9 to 23.4) / 3.4 (2.4 to 4.9) | 2.64 (1.48 to 4.71) / 2.1 (0.9 to 3.3) |
| 40–<50 | 798 | 2.1 (1.3 to 3.4) / 25.1 (22.2 to 28.3) / 5.3 (3.9 to 7.1) | 2.47 (1.54 to 3.95) / 3.1 (1.6 to 4.7) |
| 50–<60 | 1329 | 2.9 (2.1 to 3.9) / 26.9 (24.6 to 29.4) / 9.6 (8.1 to 11.3) | 3.34 (2.50 to 4.46) / 6.7 (5.2 to 8.2) |
| 60–65 | 718 | 4.7 (3.4 to 6.6) / 29.9 (26.8 to 33.5) / 10.9 (8.8 to 13.4) | 2.29 (1.69 to 3.11) / 6.1 (4.0 to 8.3) |

legend: pre · during · current

**Hoarseness — Women**

| Age | N | Prevalence (%) | Current vs. pre — Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1529 | 1.8 (1.2 to 2.6) / 31.4 (29.2 to 33.8) / 4.5 (3.6 to 5.7) | 2.56 (1.77 to 3.70) / 2.7 (1.7 to 3.8) |
| 30–<40 | 1226 | 2.8 (2.0 to 3.9) / 27.4 (25.0 to 30.0) / 4.7 (3.7 to 6.1) | 1.71 (1.24 to 2.35) / 2.0 (0.8 to 3.1) |
| 40–<50 | 1175 | 2.6 (1.8 to 3.6) / 27.0 (24.6 to 29.6) / 7.0 (5.7 to 8.6) | 2.73 (1.96 to 3.80) / 4.4 (3.1 to 5.8) |
| 50–<60 | 1907 | 4.4 (3.5 to 5.4) / 32.1 (30.1 to 34.3) / 10.0 (8.8 to 11.5) | 2.30 (1.88 to 2.82) / 5.7 (4.3 to 7.0) |
| 60–65 | 729 | 4.0 (2.8 to 5.7) / 30.5 (27.3 to 34.0) / 12.9 (10.7 to 15.6) | 3.24 (2.28 to 4.60) / 8.9 (6.5 to 11.3) |

legend: pre · during · current

**Figure C. Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. N represents the number of respondents in the respective age strata. (…continued)**

## Sore throat — Men

| Age | N | Prevalence (%) pre / during / current | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 892 | 2.9 (2.0 to 4.3) / 56.5 (53.3 to 59.9) / 4.7 (3.5 to 6.3) | 1.62 (1.09 to 2.39) / 1.8 (0.3 to 3.2) |
| 30–<40 | 839 | 3.8 (2.7 to 5.4) / 53.8 (50.5 to 57.2) / 6.1 (4.7 to 7.9) | 1.59 (1.14 to 2.22) / 2.3 (0.7 to 3.9) |
| 40–<50 | 806 | 3.1 (2.1 to 4.6) / 51.9 (48.5 to 55.4) / 5.8 (4.4 to 7.7) | 1.88 (1.23 to 2.88) / 2.7 (0.9 to 4.5) |
| 50–<60 | 1346 | 3.6 (2.8 to 4.8) / 47.5 (44.9 to 50.2) / 9.4 (8.0 to 11.1) | 2.59 (1.99 to 3.38) / 5.8 (4.3 to 7.3) |
| 60–65 | 729 | 4.3 (3.0 to 6.0) / 45.7 (42.2 to 49.4) / 9.3 (7.4 to 11.7) | 2.19 (1.60 to 3.01) / 5.1 (3.1 to 7.0) |

*pre · during · current*

## Sore throat — Women

| Age | N | Prevalence (%) pre / during / current | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1522 | 4.5 (3.6 to 5.7) / 68.5 (66.2 to 70.9) / 7.9 (6.6 to 9.4) | 1.74 (1.38 to 2.20) / 3.4 (2.0 to 4.7) |
| 30–<40 | 1237 | 4.6 (3.6 to 5.9) / 63.1 (60.5 to 65.9) / 8.2 (6.8 to 9.8) | 1.77 (1.37 to 2.30) / 3.6 (2.0 to 5.1) |
| 40–<50 | 1179 | 5.2 (4.1 to 6.6) / 59.2 (56.5 to 62.1) / 8.9 (7.4 to 10.7) | 1.72 (1.34 to 2.21) / 3.7 (2.1 to 5.4) |
| 50–<60 | 1920 | 5.4 (4.4 to 6.5) / 56.4 (54.2 to 58.6) / 11.9 (10.5 to 13.4) | 2.21 (1.82 to 2.69) / 6.5 (5.0 to 8.0) |
| 60–65 | 738 | 6.4 (4.8 to 8.4) / 51.1 (47.6 to 54.8) / 12.1 (9.9 to 14.7) | 1.89 (1.45 to 2.47) / 5.7 (3.4 to 8.0) |

*pre · during · current*

## Wheezing — Men

| Age | N | Prevalence (%) pre / during / current | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 896 | 1.2 (0.7 to 2.2) / 15.4 (13.2 to 18.0) / 5.0 (3.8 to 6.7) | 4.09 (2.34 to 7.14) / 3.8 (2.4 to 5.2) |
| 30–<40 | 842 | 2.7 (1.8 to 4.1) / 19.8 (17.3 to 22.7) / 7.8 (6.2 to 9.9) | 2.87 (1.99 to 4.14) / 5.1 (3.4 to 6.8) |
| 40–<50 | 807 | 3.6 (2.5 to 5.1) / 27.0 (24.1 to 30.3) / 8.8 (7.0 to 11.0) | 2.45 (1.77 to 3.38) / 5.2 (3.4 to 7.0) |
| 50–<60 | 1347 | 4.1 (3.2 to 5.3) / 27.3 (25.0 to 29.8) / 11.4 (9.8 to 13.2) | 2.78 (2.22 to 3.48) / 7.3 (5.8 to 8.8) |
| 60–65 | 715 | 4.5 (3.2 to 6.3) / 29.4 (26.2 to 32.9) / 14.1 (11.8 to 16.9) | 3.16 (2.30 to 4.34) / 9.7 (7.2 to 12.1) |

*pre · during · current*

## Wheezing — Women

| Age | N | Prevalence (%) pre / during / current | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1521 | 1.6 (1.1 to 2.4) / 24.8 (22.7 to 27.1) / 9.2 (7.9 to 10.8) | 5.60 (3.87 to 8.11) / 7.6 (6.2 to 9.0) |
| 30–<40 | 1237 | 1.9 (1.3 to 2.9) / 25.1 (22.8 to 27.7) / 7.4 (6.0 to 9.0) | 3.79 (2.62 to 5.48) / 5.4 (4.1 to 6.8) |
| 40–<50 | 1179 | 2.9 (2.1 to 4.0) / 25.5 (23.2 to 28.1) / 9.7 (8.1 to 11.5) | 3.35 (2.45 to 4.59) / 6.8 (5.2 to 8.4) |
| 50–<60 | 1911 | 3.1 (2.4 to 4.0) / 25.2 (23.3 to 27.2) / 10.5 (9.2 to 11.9) | 3.39 (2.70 to 4.25) / 7.4 (6.1 to 8.6) |
| 60–65 | 727 | 2.6 (1.7 to 4.1) / 21.0 (18.3 to 24.2) / 10.2 (8.2 to 12.6) | 3.89 (2.61 to 5.82) / 7.6 (5.6 to 9.6) |

*pre · during · current*

## Shortness of breath — Men

| Age | N | Prevalence (%) pre / during / current | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 890 | 1.3 (0.8 to 2.4) / 33.8 (30.9 to 37.1) / 14.0 (11.9 to 16.5) | 10.42 (6.03 to 18.01) / 12.7 (10.5 to 14.9) |
| 30–<40 | 837 | 2.2 (1.4 to 3.4) / 46.8 (43.6 to 50.3) / 20.3 (17.8 to 23.2) | 9.44 (6.00 to 14.87) / 18.2 (15.4 to 20.9) |
| 40–<50 | 809 | 4.6 (3.3 to 6.3) / 52.4 (49.1 to 56.0) / 25.5 (22.6 to 28.6) | 5.57 (4.11 to 7.54) / 20.9 (17.9 to 23.8) |
| 50–<60 | 1340 | 5.0 (4.0 to 6.3) / 53.3 (50.7 to 56.0) / 31.3 (28.9 to 33.9) | 6.25 (4.99 to 7.83) / 26.3 (23.8 to 28.7) |
| 60–65 | 727 | 6.3 (4.8 to 8.4) / 54.2 (50.7 to 57.9) / 36.6 (33.2 to 40.3) | 5.78 (4.41 to 7.57) / 30.3 (26.8 to 33.7) |

*pre · during · current*

## Shortness of breath — Women

| Age | N | Prevalence (%) pre / during / current | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1524 | 4.0 (3.1 to 5.1) / 55.4 (53.0 to 58.0) / 29.6 (27.4 to 32.0) | 7.39 (5.84 to 9.36) / 25.6 (23.4 to 27.8) |
| 30–<40 | 1234 | 3.3 (2.5 to 4.5) / 59.5 (56.8 to 62.3) / 28.9 (26.5 to 31.6) | 8.71 (6.48 to 11.70) / 25.6 (23.1 to 28.1) |
| 40–<50 | 1178 | 5.5 (4.4 to 7.0) / 59.4 (56.7 to 62.3) / 35.2 (32.6 to 38.1) | 6.38 (5.08 to 8.02) / 29.7 (27.0 to 32.4) |
| 50–<60 | 1912 | 6.7 (5.7 to 8.0) / 60.1 (58.0 to 62.4) / 39.3 (37.1 to 41.5) | 5.82 (4.95 to 6.84) / 32.5 (30.3 to 34.7) |
| 60–65 | 732 | 9.3 (7.4 to 11.6) / 53.8 (50.3 to 57.6) / 39.1 (35.7 to 42.8) | 4.21 (3.40 to 5.20) / 29.8 (26.4 to 33.2) |

*pre · during · current*

**Figure C. Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. N represents the number of respondents in the respective age strata. (…continued)**

**Chest pain**
**Men**

| | N | Prevalence (%) | Current vs. pre Prev. ratio Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 894 | 1.7 (1.0 to 2.8) 17.0 (14.7 to 19.7) 8.1 (6.5 to 10.1) | 4.80 (3.04 to 7.59) 6.4 (4.7 to 8.0) |
| 30–<40 | 847 | 1.9 (1.2 to 3.1) 24.3 (21.6 to 27.4) 10.2 (8.3 to 12.4) | 5.38 (3.41 to 8.47) 8.3 (6.4 to 10.2) |
| 40–<50 | 810 | 1.5 (0.8 to 2.6) 27.9 (25.0 to 31.2) 10.6 (8.7 to 13.0) | 7.17 (4.18 to 12.28) 9.1 (7.1 to 11.2) |
| 50–<60 | 1358 | 1.4 (0.9 to 2.2) 22.0 (19.9 to 24.3) 8.7 (7.3 to 10.3) | 6.21 (4.11 to 9.38) 7.3 (5.9 to 8.7) |
| 60–65 | 733 | 2.5 (1.6 to 3.9) 21.4 (18.6 to 24.6) 9.3 (7.4 to 11.6) | 3.78 (2.48 to 5.75) 6.8 (4.9 to 8.8) |

■ pre ■ during ■ current

**Chest pain**
**Women**

| | N | Prevalence (%) | Current vs. pre Prev. ratio Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1529 | 1.8 (1.3 to 2.6) 26.2 (24.0 to 28.5) 11.0 (9.5 to 12.7) | 6.00 (4.16 to 8.65) 9.2 (7.6 to 10.7) |
| 30–<40 | 1237 | 1.1 (0.6 to 1.8) 28.9 (26.4 to 31.5) 9.4 (7.9 to 11.2) | 8.92 (5.24 to 15.19) 8.3 (6.7 to 9.9) |
| 40–<50 | 1184 | 2.4 (1.7 to 3.5) 32.9 (30.4 to 35.7) 12.2 (10.4 to 14.2) | 4.97 (3.49 to 7.06) 9.7 (7.9 to 11.6) |
| 50–<60 | 1929 | 1.8 (1.3 to 2.5) 30.1 (28.1 to 32.2) 12.2 (10.8 to 13.7) | 6.91 (4.97 to 9.60) 10.4 (9.0 to 11.9) |
| 60–65 | 741 | 1.3 (0.7 to 2.5) 22.8 (20.0 to 26.0) 9.0 (7.2 to 11.4) | 6.70 (3.67 to 12.22) 7.7 (5.7 to 9.7) |

■ pre ■ during ■ current

**Vomiting**
**Men**

| | N | Prevalence (%) | Current vs. pre Prev. ratio Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 896 | 0.6 (0.2 to 1.3) 2.9 (2.0 to 4.2) 0.7 (0.3 to 1.5) | 1.20 (0.47 to 3.09) 0.1 (–0.5 to 0.7) |
| 30–<40 | 846 | 0.4 (0.1 to 1.1) 2.2 (1.4 to 3.5) 0.6 (0.2 to 1.4) | 1.67 (0.40 to 6.97) 0.2 (–0.4 to 0.9) |
| 40–<50 | 816 | 1.0 (0.5 to 2.0) 3.2 (2.2 to 4.7) 0.1 (0.0 to 0.9) | 0.13 (0.02 to 1.00) –0.9 (–1.6 to –0.1) |
| 50–<60 | 1361 | 0.3 (0.1 to 0.8) 4.9 (3.9 to 6.2) 0.7 (0.4 to 1.4) | 2.50 (1.04 to 6.01) 0.4 (0.0 to 0.8) |
| 60–65 | 730 | 0.4 (0.1 to 1.3) 3.0 (2.0 to 4.5) 0.4 (0.1 to 1.3) | 1.00 (0.27 to 3.69) 0.0 (–0.5 to 0.5) |

■ pre ■ during ■ current

**Vomiting**
**Women**

| | N | Prevalence (%) | Current vs. pre Prev. ratio Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1532 | 0.5 (0.2 to 1.0) 3.3 (2.5 to 4.3) 0.9 (0.5 to 1.5) | 2.00 (0.93 to 4.31) 0.5 (–0.0 to 1.0) |
| 30–<40 | 1239 | 0.6 (0.3 to 1.2) 4.6 (3.6 to 5.9) 0.7 (0.4 to 1.4) | 1.29 (0.51 to 3.24) 0.2 (–0.4 to 0.8) |
| 40–<50 | 1183 | 0.5 (0.2 to 1.1) 6.1 (4.9 to 7.6) 0.8 (0.5 to 1.6) | 1.67 (0.65 to 4.30) 0.3 (–0.3 to 1.0) |
| 50–<60 | 1933 | 0.6 (0.3 to 1.0) 7.0 (5.9 to 8.2) 1.3 (0.9 to 1.9) | 2.27 (1.27 to 4.06) 0.7 (0.2 to 1.2) |
| 60–65 | 746 | 0.3 (0.1 to 1.1) 7.6 (6.0 to 9.8) 0.7 (0.3 to 1.6) | 2.50 (0.85 to 7.31) 0.4 (–0.1 to 0.9) |

■ pre ■ during ■ current

**Nausea**
**Men**

| | N | Prevalence (%) | Current vs. pre Prev. ratio Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 896 | 1.0 (0.5 to 1.9) 10.8 (9.0 to 13.1) 2.1 (1.4 to 3.3) | 2.11 (1.12 to 3.99) 1.1 (0.2 to 2.0) |
| 30–<40 | 842 | 0.7 (0.3 to 1.6) 11.2 (9.2 to 13.5) 1.4 (0.8 to 2.5) | 2.00 (0.84 to 4.75) 0.7 (–0.2 to 1.6) |
| 40–<50 | 815 | 1.3 (0.8 to 2.4) 13.9 (11.7 to 16.5) 2.2 (1.4 to 3.5) | 1.64 (0.86 to 3.10) 0.9 (–0.2 to 2.0) |
| 50–<60 | 1364 | 0.9 (0.5 to 1.5) 15.3 (13.5 to 17.4) 2.9 (2.2 to 4.0) | 3.33 (1.92 to 5.79) 2.1 (1.2 to 2.9) |
| 60–65 | 733 | 0.5 (0.2 to 1.5) 19.0 (16.3 to 22.0) 3.0 (2.0 to 4.5) | 5.50 (2.16 to 14.00) 2.5 (1.3 to 3.6) |

■ pre ■ during ■ current

**Nausea**
**Women**

| | N | Prevalence (%) | Current vs. pre Prev. ratio Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1530 | 3.0 (2.3 to 4.0) 17.3 (15.5 to 19.3) 5.6 (4.5 to 6.8) | 1.85 (1.42 to 2.40) 2.5 (1.5 to 3.6) |
| 30–<40 | 1244 | 2.1 (1.4 to 3.1) 18.8 (16.8 to 21.1) 4.1 (3.1 to 5.4) | 1.96 (1.32 to 2.92) 2.0 (0.8 to 3.2) |
| 40–<50 | 1187 | 2.0 (1.4 to 3.0) 20.5 (18.3 to 22.9) 5.7 (4.5 to 7.2) | 2.83 (1.87 to 4.30) 3.7 (2.3 to 5.1) |
| 50–<60 | 1919 | 1.7 (1.2 to 2.4) 24.0 (22.1 to 26.0) 6.5 (5.5 to 7.7) | 3.76 (2.75 to 5.13) 4.7 (3.7 to 5.8) |
| 60–65 | 750 | 1.5 (0.8 to 2.6) 27.5 (24.5 to 30.9) 6.5 (5.0 to 8.6) | 4.45 (2.54 to 7.80) 5.1 (3.4 to 6.8) |

■ pre ■ during ■ current

**Figure C. Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. N represents the number of respondents in the respective age strata. (…continued)**

## Abdominal pain — Men

| Age | N | Prevalence (%) pre / during / current | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 895 | 3.2 (2.3 to 4.6) / 9.4 (7.7 to 11.5) / 3.4 (2.4 to 4.8) | 1.03 (0.76 to 1.40) / 0.1 (−0.9 to 1.1) |
| 30–<40 | 843 | 2.5 (1.6 to 3.8) / 7.4 (5.8 to 9.3) / 3.3 (2.3 to 4.8) | 1.33 (0.89 to 2.00) / 0.8 (−0.3 to 2.0) |
| 40–<50 | 810 | 2.6 (1.7 to 4.0) / 10.9 (8.9 to 13.2) / 4.2 (3.0 to 5.8) | 1.62 (1.16 to 2.27) / 1.6 (0.5 to 2.7) |
| 50–<60 | 1356 | 2.0 (1.4 to 2.9) / 10.0 (8.5 to 11.7) / 4.0 (3.1 to 5.2) | 2.00 (1.44 to 2.78) / 2.0 (1.1 to 2.9) |
| 60–65 | 735 | 2.4 (1.6 to 3.9) / 12.7 (10.5 to 15.3) / 6.3 (4.7 to 8.3) | 2.56 (1.74 to 3.76) / 3.8 (2.3 to 5.3) |

## Abdominal pain — Women

| Age | N | Prevalence (%) pre / during / current | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1528 | 6.2 (5.1 to 7.6) / 13.8 (12.2 to 15.7) / 7.3 (6.1 to 8.8) | 1.18 (1.01 to 1.37) / 1.1 (0.1 to 2.1) |
| 30–<40 | 1238 | 2.7 (2.0 to 3.8) / 12.8 (11.0 to 14.8) / 3.2 (2.4 to 4.4) | 1.18 (0.87 to 1.59) / 0.5 (−0.4 to 1.4) |
| 40–<50 | 1184 | 4.0 (3.0 to 5.3) / 15.5 (13.5 to 17.7) / 7.3 (5.9 to 8.9) | 1.83 (1.40 to 2.39) / 3.3 (1.9 to 4.7) |
| 50–<60 | 1927 | 3.0 (2.3 to 3.8) / 15.9 (14.4 to 17.7) / 7.2 (6.1 to 8.4) | 2.42 (1.93 to 3.04) / 4.2 (3.2 to 5.2) |
| 60–65 | 746 | 2.4 (1.5 to 3.8) / 16.8 (14.3 to 19.7) / 6.6 (5.0 to 8.6) | 2.72 (1.82 to 4.07) / 4.2 (2.6 to 5.7) |

## Diarrhea — Men

| Age | N | Prevalence (%) pre / during / current | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 897 | 3.9 (2.8 to 5.4) / 13.4 (11.3 to 15.8) / 5.0 (3.8 to 6.7) | 1.29 (0.99 to 1.67) / 1.1 (−0.0 to 2.3) |
| 30–<40 | 843 | 3.6 (2.5 to 5.1) / 16.8 (14.5 to 19.6) / 5.0 (3.7 to 6.7) | 1.40 (1.07 to 1.83) / 1.4 (0.3 to 2.6) |
| 40–<50 | 812 | 4.3 (3.1 to 6.0) / 21.3 (18.7 to 24.3) / 5.9 (4.5 to 7.8) | 1.37 (1.05 to 1.79) / 1.6 (0.3 to 2.9) |
| 50–<60 | 1359 | 4.1 (3.2 to 5.3) / 21.7 (19.6 to 24.0) / 7.1 (5.8 to 8.6) | 1.71 (1.41 to 2.09) / 2.9 (1.9 to 4.0) |
| 60–65 | 729 | 3.2 (2.1 to 4.7) / 18.9 (16.3 to 22.0) / 6.7 (5.1 to 8.8) | 2.13 (1.52 to 2.99) / 3.6 (2.0 to 5.1) |

## Diarrhea — Women

| Age | N | Prevalence (%) pre / during / current | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1529 | 5.6 (4.5 to 6.8) / 19.8 (17.9 to 21.9) / 8.5 (7.2 to 10.0) | 1.53 (1.30 to 1.80) / 2.9 (1.8 to 4.1) |
| 30–<40 | 1237 | 3.5 (2.6 to 4.7) / 21.5 (19.3 to 23.9) / 6.1 (4.9 to 7.6) | 1.77 (1.38 to 2.27) / 2.7 (1.5 to 3.8) |
| 40–<50 | 1183 | 3.6 (2.7 to 4.9) / 24.1 (21.8 to 26.7) / 6.7 (5.4 to 8.3) | 1.84 (1.41 to 2.39) / 3.0 (1.8 to 4.3) |
| 50–<60 | 1933 | 4.4 (3.6 to 5.5) / 24.4 (22.5 to 26.4) / 7.9 (6.8 to 9.2) | 1.78 (1.51 to 2.09) / 3.5 (2.5 to 4.4) |
| 60–65 | 748 | 4.1 (2.9 to 5.8) / 26.9 (23.9 to 30.2) / 9.5 (7.6 to 11.8) | 2.29 (1.71 to 3.06) / 5.3 (3.6 to 7.1) |

## Chills — Men

| Age | N | Prevalence (%) pre / during / current | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 896 | 0.7 (0.3 to 1.5) / 37.7 (34.7 to 41.0) / 0.9 (0.4 to 1.8) | 1.33 (0.50 to 3.55) / 0.2 (−0.5 to 1.0) |
| 30–<40 | 841 | 0.8 (0.4 to 1.7) / 41.5 (38.3 to 45.0) / 1.0 (0.5 to 1.9) | 1.14 (0.48 to 2.72) / 0.1 (−0.7 to 0.9) |
| 40–<50 | 809 | 1.9 (1.1 to 3.1) / 44.6 (41.3 to 48.2) / 1.7 (1.0 to 2.9) | 0.93 (0.49 to 1.79) / −0.1 (−1.3 to 1.0) |
| 50–<60 | 1354 | 0.8 (0.5 to 1.5) / 41.6 (39.0 to 44.3) / 1.5 (1.0 to 2.3) | 1.82 (0.92 to 3.61) / 0.7 (−0.1 to 1.4) |
| 60–65 | 726 | 0.7 (0.3 to 1.6) / 35.4 (32.1 to 39.1) / 1.8 (1.0 to 3.1) | 2.60 (0.98 to 6.88) / 1.1 (0.0 to 2.2) |

## Chills — Women

| Age | N | Prevalence (%) pre / during / current | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1527 | 1.0 (0.6 to 1.7) / 40.5 (38.1 to 43.0) / 1.9 (1.3 to 2.7) | 1.81 (1.13 to 2.91) / 0.9 (0.2 to 1.5) |
| 30–<40 | 1235 | 0.6 (0.3 to 1.2) / 40.8 (38.2 to 43.6) / 2.0 (1.4 to 3.0) | 3.57 (1.68 to 7.60) / 1.5 (0.7 to 2.3) |
| 40–<50 | 1183 | 1.3 (0.8 to 2.1) / 42.6 (39.9 to 45.5) / 2.7 (1.9 to 3.8) | 2.13 (1.22 to 3.73) / 1.4 (0.4 to 2.5) |
| 50–<60 | 1927 | 0.8 (0.5 to 1.4) / 42.3 (40.2 to 44.6) / 2.9 (2.2 to 3.8) | 3.50 (2.02 to 6.05) / 2.1 (1.2 to 2.9) |
| 60–65 | 740 | 1.1 (0.5 to 2.2) / 35.0 (31.7 to 38.6) / 2.7 (1.8 to 4.2) | 2.50 (1.21 to 5.17) / 1.6 (0.4 to 2.9) |

Legend: pre / during / current

**Figure C.** Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. N represents the number of respondents in the respective age strata. (…continued)

**Figure C. Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. N represents the number of respondents in the respective age strata. (…continued)**

## Arthralgia — Men

| | N | Prevalence (%) | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 894 | 2.8 (1.9 to 4.1) / 29.1 (26.3 to 32.2) / 3.8 (2.7 to 5.3) | 1.36 (0.99 to 1.88) / 1.0 (–0.0 to 2.1) |
| 30–<40 | 847 | 3.1 (2.1 to 4.5) / 34.6 (31.5 to 37.9) / 7.3 (5.8 to 9.3) | 2.38 (1.64 to 3.46) / 4.3 (2.5 to 6.0) |
| 40–<50 | 803 | 7.1 (5.5 to 9.1) / 41.0 (37.7 to 44.5) / 15.4 (13.1 to 18.2) | 2.18 (1.74 to 2.72) / 8.3 (6.1 to 10.6) |
| 50–<60 | 1343 | 10.5 (9.0 to 12.3) / 47.1 (44.5 to 49.9) / 21.8 (19.7 to 24.1) | 2.08 (1.82 to 2.37) / 11.3 (9.4 to 13.2) |
| 60–65 | 725 | 11.9 (9.7 to 14.5) / 46.5 (43.0 to 50.3) / 25.4 (22.4 to 28.8) | 2.14 (1.81 to 2.52) / 13.5 (10.8 to 16.2) |

pre / during / current

## Arthralgia — Women

| | N | Prevalence (%) | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1525 | 4.1 (3.2 to 5.2) / 34.8 (32.4 to 37.2) / 8.3 (7.1 to 9.8) | 2.05 (1.67 to 2.52) / 4.3 (3.1 to 5.4) |
| 30–<40 | 1241 | 3.5 (2.7 to 4.7) / 37.3 (34.7 to 40.1) / 10.8 (9.2 to 12.7) | 3.05 (2.35 to 3.95) / 7.3 (5.7 to 8.8) |
| 40–<50 | 1177 | 8.6 (7.1 to 10.3) / 45.8 (43.0 to 48.7) / 21.3 (19.1 to 23.8) | 2.49 (2.11 to 2.92) / 12.7 (10.7 to 14.8) |
| 50–<60 | 1909 | 17.4 (15.8 to 19.2) / 52.8 (50.6 to 55.0) / 32.1 (30.1 to 34.3) | 1.85 (1.70 to 2.00) / 14.7 (12.9 to 16.5) |
| 60–65 | 728 | 20.1 (17.3 to 23.2) / 51.0 (47.5 to 54.7) / 32.7 (29.5 to 36.3) | 1.63 (1.46 to 1.82) / 12.6 (10.0 to 15.3) |

pre / during / current

## Paresthesia — Men

| | N | Prevalence (%) | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 895 | 1.7 (1.0 to 2.8) / 8.9 (7.3 to 11.0) / 4.2 (3.1 to 5.8) | 2.53 (1.60 to 4.00) / 2.6 (1.4 to 3.8) |
| 30–<40 | 845 | 1.8 (1.1 to 2.9) / 11.4 (9.4 to 13.7) / 5.7 (4.3 to 7.5) | 3.20 (2.00 to 5.11) / 3.9 (2.4 to 5.4) |
| 40–<50 | 813 | 3.2 (2.2 to 4.7) / 16.2 (13.9 to 19.0) / 10.0 (8.1 to 12.3) | 3.12 (2.22 to 4.37) / 6.8 (4.9 to 8.6) |
| 50–<60 | 1348 | 4.2 (3.3 to 5.5) / 19.4 (17.4 to 21.6) / 12.5 (10.8 to 14.4) | 2.95 (2.36 to 3.67) / 8.2 (6.7 to 9.8) |
| 60–65 | 727 | 6.6 (5.0 to 8.7) / 23.2 (20.4 to 26.5) / 16.8 (14.3 to 19.7) | 2.54 (2.02 to 3.21) / 10.2 (7.9 to 12.5) |

pre / during / current

## Paresthesia — Women

| | N | Prevalence (%) | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1533 | 2.3 (1.6 to 3.2) / 11.5 (10.1 to 13.3) / 6.8 (5.6 to 8.2) | 2.97 (2.21 to 3.99) / 4.5 (3.4 to 5.6) |
| 30–<40 | 1242 | 3.1 (2.3 to 4.3) / 17.0 (15.0 to 19.2) / 10.8 (9.2 to 12.7) | 3.44 (2.60 to 4.55) / 7.6 (6.1 to 9.2) |
| 40–<50 | 1181 | 5.3 (4.2 to 6.8) / 20.1 (17.9 to 22.5) / 15.2 (13.3 to 17.4) | 2.86 (2.31 to 3.53) / 9.9 (8.1 to 11.7) |
| 50–<60 | 1921 | 7.0 (6.0 to 8.3) / 22.6 (20.8 to 24.5) / 17.4 (15.8 to 19.2) | 2.48 (2.16 to 2.85) / 10.4 (8.9 to 11.9) |
| 60–65 | 731 | 6.4 (4.9 to 8.5) / 21.6 (18.8 to 24.8) / 17.2 (14.7 to 20.2) | 2.68 (2.11 to 3.41) / 10.8 (8.4 to 13.2) |

pre / during / current

## Sleep disorder — Men

| | N | Prevalence (%) | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 899 | 5.3 (4.1 to 7.0) / 18.2 (15.9 to 21.0) / 11.1 (9.2 to 13.4) | 2.08 (1.67 to 2.59) / 5.8 (4.1 to 7.4) |
| 30–<40 | 847 | 5.7 (4.3 to 7.5) / 21.7 (19.1 to 24.7) / 13.1 (11.0 to 15.6) | 2.31 (1.80 to 2.98) / 7.4 (5.3 to 9.6) |
| 40–<50 | 813 | 11.9 (9.9 to 14.4) / 30.1 (27.1 to 33.5) / 22.9 (20.2 to 26.0) | 1.92 (1.64 to 2.25) / 10.9 (8.5 to 13.4) |
| 50–<60 | 1357 | 11.2 (9.6 to 13.0) / 34.6 (32.2 to 37.3) / 25.4 (23.2 to 27.8) | 2.27 (1.99 to 2.58) / 14.2 (12.2 to 16.3) |
| 60–65 | 730 | 14.5 (12.2 to 17.3) / 34.0 (30.7 to 37.6) / 26.6 (23.6 to 30.0) | 1.83 (1.59 to 2.11) / 12.1 (9.4 to 14.7) |

pre / during / current

## Sleep disorder — Women

| | N | Prevalence (%) | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1529 | 10.3 (8.9 to 11.9) / 26.8 (24.7 to 29.1) / 19.2 (17.3 to 21.2) | 1.87 (1.66 to 2.10) / 8.9 (7.3 to 10.5) |
| 30–<40 | 1240 | 10.5 (8.9 to 12.3) / 28.9 (26.5 to 31.5) / 20.9 (18.7 to 23.3) | 1.99 (1.74 to 2.28) / 10.4 (8.5 to 12.3) |
| 40–<50 | 1176 | 16.8 (14.7 to 19.0) / 37.3 (34.7 to 40.2) / 32.3 (29.7 to 35.1) | 1.93 (1.73 to 2.15) / 15.6 (13.2 to 17.9) |
| 50–<60 | 1936 | 28.7 (26.8 to 30.8) / 47.8 (45.7 to 50.1) / 42.5 (40.4 to 44.8) | 1.48 (1.40 to 1.57) / 13.8 (11.9 to 15.7) |
| 60–65 | 728 | 28.4 (25.3 to 31.9) / 44.5 (41.0 to 48.3) / 38.6 (35.2 to 42.3) | 1.36 (1.24 to 1.48) / 10.2 (7.3 to 13.0) |

pre / during / current

**Figure C. Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. N represents the number of respondents in the respective age strata. (…continued)**

## Chronic fatigue — Men

| Age | N | Prevalence (%) | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 896 | 1.7 (1.0 to 2.8) / 29.7 (26.8 to 32.8) / 13.8 (11.8 to 16.3) | 8.27 (5.14 to 13.29) / 12.2 (10.0 to 14.3) |
| 30–<40 | 845 | 2.0 (1.3 to 3.2) / 34.6 (31.5 to 37.9) / 17.2 (14.8 to 19.9) | 8.53 (5.42 to 13.42) / 15.1 (12.7 to 17.6) |
| 40–<50 | 807 | 3.8 (2.7 to 5.4) / 40.8 (37.5 to 44.3) / 22.9 (20.2 to 26.0) | 5.97 (4.28 to 8.31) / 19.1 (16.3 to 21.9) |
| 50–<60 | 1348 | 3.0 (2.2 to 4.0) / 44.6 (42.0 to 47.3) / 27.0 (24.7 to 29.5) | 9.10 (6.76 to 12.25) / 24.0 (21.7 to 26.4) |
| 60–65 | 727 | 5.8 (4.3 to 7.7) / 44.3 (40.8 to 48.1) / 28.6 (25.5 to 32.1) | 4.95 (3.74 to 6.55) / 22.8 (19.6 to 26.0) |

■ pre ■ during ■ current

## Chronic fatigue — Women

| Age | N | Prevalence (%) | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1529 | 4.6 (3.6 to 5.8) / 42.2 (39.8 to 44.8) / 23.4 (21.4 to 25.6) | 5.11 (4.12 to 6.34) / 18.8 (16.8 to 20.9) |
| 30–<40 | 1239 | 4.6 (3.6 to 5.9) / 44.4 (41.7 to 47.2) / 25.7 (23.4 to 28.3) | 5.60 (4.39 to 7.13) / 21.1 (18.8 to 23.5) |
| 40–<50 | 1174 | 6.8 (5.5 to 8.4) / 49.4 (46.6 to 52.3) / 35.0 (32.4 to 37.8) | 5.14 (4.20 to 6.29) / 28.2 (25.5 to 30.9) |
| 50–<60 | 1912 | 7.7 (6.6 to 9.0) / 52.6 (50.4 to 54.9) / 35.7 (33.6 to 37.9) | 4.61 (3.98 to 5.33) / 27.9 (25.9 to 30.0) |
| 60–65 | 733 | 6.3 (4.7 to 8.3) / 49.5 (46.0 to 53.3) / 32.3 (29.1 to 35.9) | 5.15 (3.92 to 6.78) / 26.1 (22.6 to 29.5) |

■ pre ■ during ■ current

## Rapid physical exhaustion — Men

| Age | N | Prevalence (%) | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 894 | 1.6 (0.9 to 2.6) / 50.7 (47.5 to 54.1) / 18.8 (16.4 to 21.5) | 12.00 (7.22 to 19.94) / 17.2 (14.7 to 19.7) |
| 30–<40 | 844 | 1.4 (0.8 to 2.5) / 56.6 (53.4 to 60.1) / 21.7 (19.1 to 24.6) | 15.25 (8.69 to 26.77) / 20.3 (17.5 to 23.1) |
| 40–<50 | 807 | 2.1 (1.3 to 3.4) / 61.6 (58.3 to 65.0) / 31.2 (28.2 to 34.6) | 14.82 (9.33 to 23.55) / 29.1 (25.9 to 32.3) |
| 50–<60 | 1342 | 2.8 (2.1 to 3.9) / 64.8 (62.3 to 67.4) / 36.3 (33.8 to 39.0) | 12.82 (9.39 to 17.50) / 33.5 (30.9 to 36.1) |
| 60–65 | 724 | 5.4 (4.0 to 7.3) / 63.3 (59.8 to 66.9) / 39.2 (35.8 to 42.9) | 7.28 (5.40 to 9.83) / 33.8 (30.2 to 37.4) |

■ pre ■ during ■ current

## Rapid physical exhaustion — Women

| Age | N | Prevalence (%) | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1520 | 3.8 (3.0 to 4.9) / 69.1 (66.8 to 71.4) / 32.4 (30.1 to 34.8) | 8.48 (6.62 to 10.87) / 28.6 (26.2 to 30.9) |
| 30–<40 | 1227 | 3.4 (2.5 to 4.6) / 69.0 (66.5 to 71.7) / 33.7 (31.1 to 36.4) | 9.83 (7.34 to 13.17) / 30.2 (27.6 to 32.9) |
| 40–<50 | 1172 | 4.9 (3.8 to 6.3) / 71.6 (69.1 to 74.2) / 42.4 (39.7 to 45.3) | 8.72 (6.81 to 11.17) / 37.5 (34.7 to 40.4) |
| 50–<60 | 1911 | 6.3 (5.3 to 7.5) / 74.7 (72.7 to 76.6) / 47.8 (45.6 to 50.1) | 7.55 (6.37 to 8.94) / 41.4 (39.1 to 43.7) |
| 60–65 | 734 | 6.1 (4.6 to 8.1) / 72.9 (69.7 to 76.2) / 48.1 (44.6 to 51.8) | 7.84 (5.94 to 10.35) / 42.0 (38.3 to 45.6) |

■ pre ■ during ■ current

## Skin rash — Men

| Age | N | Prevalence (%) | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 892 | 3.0 (2.1 to 4.4) / 4.3 (3.1 to 5.8) / 3.9 (2.8 to 5.4) | 1.30 (0.99 to 1.70) / 0.9 (−0.0 to 1.8) |
| 30–<40 | 848 | 2.7 (1.8 to 4.1) / 3.9 (2.8 to 5.4) / 4.2 (3.1 to 5.8) | 1.57 (1.08 to 2.26) / 1.5 (0.3 to 2.8) |
| 40–<50 | 801 | 1.5 (0.9 to 2.6) / 5.6 (4.2 to 7.5) / 4.0 (2.8 to 5.6) | 2.67 (1.63 to 4.35) / 2.5 (1.3 to 3.7) |
| 50–<60 | 1358 | 3.8 (2.9 to 4.9) / 7.7 (6.4 to 9.2) / 6.0 (4.9 to 7.4) | 1.61 (1.32 to 1.96) / 2.3 (1.3 to 3.2) |
| 60–65 | 731 | 4.1 (2.9 to 5.8) / 8.3 (6.6 to 10.6) / 6.4 (4.9 to 8.5) | 1.57 (1.17 to 2.10) / 2.3 (0.8 to 3.8) |

■ pre ■ during ■ current

## Skin rash — Women

| Age | N | Prevalence (%) | Current vs. pre Prev. ratio / Prev. difference (%) |
|---|---|---|---|
| 18–<30 | 1527 | 3.4 (2.6 to 4.4) / 6.5 (5.4 to 7.9) / 5.9 (4.8 to 7.2) | 1.73 (1.40 to 2.14) / 2.5 (1.5 to 3.4) |
| 30–<40 | 1233 | 3.7 (2.8 to 5.0) / 6.2 (5.0 to 7.8) / 5.1 (4.0 to 6.5) | 1.37 (1.07 to 1.76) / 1.4 (0.3 to 2.5) |
| 40–<50 | 1182 | 3.0 (2.1 to 4.1) / 8.0 (6.6 to 9.7) / 5.3 (4.2 to 6.8) | 1.80 (1.32 to 2.45) / 2.4 (1.2 to 3.6) |
| 50–<60 | 1934 | 3.9 (3.1 to 4.8) / 8.6 (7.4 to 9.9) / 6.7 (5.6 to 7.9) | 1.72 (1.42 to 2.08) / 2.8 (1.8 to 3.7) |
| 60–65 | 742 | 3.2 (2.2 to 4.8) / 9.8 (7.9 to 12.2) / 6.6 (5.0 to 8.7) | 2.04 (1.42 to 2.94) / 3.4 (1.7 to 5.0) |

■ pre ■ during ■ current

**Figure C. Prevalence of symptoms before (pre), during, and 6-12 months after (current) after the SARS-CoV-2 infection, including prevalence ratio (current divided by pre) and prevalence difference (current minus pre) with 95 % confidence intervals according to age categories and sex. N represents the number of respondents in the respective age strata. (…continued)**

**Figure D. Frequency of symptoms 6-12 months after acute infection, given the symptom was not present before the infection, stratified according to sex with grade of impairment (top panel) and medical treatment (bottom panel).**

**Table A. Characteristics by two or more vs less than two new symptoms (not present before the infection)**

| | Less than two symptoms | | Two or more symptoms | |
|---|---|---|---|---|
| | N | Number (%) or mean (standard deviation) | N | Number (%) or mean (standard deviation) |
| Age (years), mean (sd) | 5489 | 42.5 (13.9) | 6030 | 45.4 (13.3) |
| Age class (years), N (%) | | | | |
| <30 | | 1361 (24.8) | | 1095 (18.2) |
| 30 - <40 | | 1118 (20.4) | | 1016 (16.9) |
| 40 - <50 | 5489 | 923 (16.8) | 6030 | 1117 (18.5) |
| 50 - <60 | | 1405 (25.6) | | 1959 (32.5) |
| ≥ 60 | | 682 (12.4) | | 843 (14.0) |
| Sex, N (%) | | | | |
| Male | 5489 | 2600 (47.4) | 6030 | 2139 (35.5) |
| Female | | 2889 (52.6) | | 3891 (64.5) |
| Marital status, N (%) | | | | |
| Single | | 1736 (32.2) | | 1638 (27.7) |
| Married/living together | 5387 | 3464 (64.3) | 5923 | 3981 (67.2) |
| Living apart | | 138 (2.6) | | 218 (3.7) |
| Widowed | | 49 (0.9) | | 86 (1.5) |
| University entrance qualification, N (%) | 5472 | | 6016 | |
| Yes | | 3094 (56.5) | | 2929 (48.7) |
| No | | 2378 (43.5) | | 3087 (50.9) |
| Place of birth, N (%) | | | | |
| Germany | 5465 | 4848 (88.7) | 6014 | 5366 (89.2) |
| Other | | 617 (11.3) | | 648 (10.8) |
| Nationality, N (%) | | | | |
| German | 5472 | 5145 (94.0) | 6023 | 5700 (94.6) |
| Other* | | 330 (6.0) | | 323 (5.4) |
| Place of residence, N (%) | | | | |
| Mostly urban | | 3380 (63.5) | | 3755 (64.1) |
| Partly urban | 5325 | 1083 (20.3) | 5857 | 1208 (20.6) |
| Mostly rural | | 862 (16.2) | | 894 (15.3) |
| Pre-pandemic employment, N (%) | | | | |
| Full time | | 3141 (57.6) | | 3361 (56.1) |
| Part time | 5454 | 1356 (24.9) | 5989 | 1817 (30.3) |
| Studying/vocational education | | 641 (11.8) | | 497 (8.3) |
| None | | 316 (5.8) | | 314 (5.2) |
| Current employment, N (%) | | | | |
| Full time | | 3080 (56.5) | | 3154 (52.5) |
| Part time | 5455 | 1353 (24.8) | 6006 | 1816 (30.2) |
| Studying/vocational education | | 564 (10.3) | | 463 (7.7) |
| None | | 458 (8.4) | | 573 (9.5) |
| Smoking status, N (%) | | | | |
| Current | | 526 (9.6) | | 644 (10.7) |
| Former | 5475 | 1172 (21.4) | 6015 | 1653 (27.5) |
| Never | | 3777 (69.0) | | 3718 (61.8) |
| BMI (kg/m²), mean (sd) | 5446 | 25.5 (4.8) | 5984 | 26.5 (5.6) |
| Obese (≥30 kg/m²), N (%) | 5446 | 813 (14.9) | 5984 | 1313 (21.9) |
| Pre-existing conditions, N (%) | | | | |

| | Less than two symptoms | | Two or more symptoms | |
|---|---|---|---|---|
| | N | Number (%) or mean (standard deviation) | N | Number (%) or mean (standard deviation) |
| Musculoskeletal disorders (including rheumatism) | 5385 | 1171 (21.8) | 5905 | 2105 (35.7) |
| Cardiovascular disorders (including hypertension) | 5400 | 739 (13.7) | 5923 | 1216 (20.5) |
| Neurological or sensory disorders | 5394 | 698 (12.9) | 5929 | 1141 (19.2) |
| Metabolic disorders | 5432 | 709 (13.1) | 5961 | 1275 (21.4) |
| Mental disorders | 5403 | 492 (9.1) | 5919 | 959 (16.2) |
| Respiratory diseases | 5394 | 492 (9.1) | 5917 | 875 (14.8) |
| Dermatological diseases | 5432 | 510 (9.4) | 5949 | 729 (12.3) |
| Cancer | 5346 | 160 (3.0) | 5820 | 222 (3.8) |
| Time since positive PCR test (months), mean (sd) | 5392 | 8.5 (1.6) | 5954 | 8.5 (1.6) |
| Treatment of acute SARS-CoV-2 infection, N (%) | | | | |
| No medical care | 5445 | 4823 (88.6) | 5976 | 4028 (67.4) |
| Outpatient care | | 529 (9.7) | | 1636 (27.4) |
| Inpatient care (without ICU) | | 74 (1.4) | | 237 (4.0) |
| Intensive care | | 19 (0.4) | | 75 (1.3) |
| Vaccinated before positive PCR test, N (%) | | | | |
| Yes | 5364 | 110 (2.1) | 5899 | 105 (1.8) |
| No | | 5255 (98.0) | | 5794 (98.2) |

**Figure E. Co-occurrence network of symptom clusters 6-12 months after acute infection, along with contributing individual symptoms of grade moderate to strong. The outer circles represent individual symptoms. Circle area represents the proportion of patients with that symptom. These are linked to the inner circles, which represent symptom clusters. Width of the link lines again represents the proportion of patients with that symptom. Circle area for the clusters represents the proportion of patients with at least one symptom from that cluster. Central links between symptom clusters represent co-occurrence of symptom clusters. Link width represents the degree of co-occurrence. Based on data of N=11 536 participants. Only symptoms not present before the acute SARS-CoV-2 infection were considered.**

**Table B. Fatigue assessment scale (FAS) scores by new (not present before the infection) self-reported fatigue (as most prevalent symptom cluster)**

| Fatigue assessment scale (FAS) | All N=10 956 | No fatigue N=6879 | Fatigue with grade of impairment | | |
| --- | --- | --- | --- | --- | --- |
| | | | none/light N=1554 | moderate N=1443 | strong N=1080 |
| Total score, mean (sd) | 21.7 (8.9) | 17.7 (6.5) | 23.5 (6.4) | 28.7 (6.9) | 35.5 (7.3) |
| Physical sub-scale, mean (sd) | 11.9 (4.9) | 9.7 (3.7) | 13.0 (3.4) | 15.9 (3.5) | 19.3 (3.3) |
| Mental sub-scale, mean (sd) | 9.8 (4.5) | 8.0 (3.3) | 10.6 (3.6) | 12.7 (4.1) | 16.1 (4.7) |
| Proportion with FAS score >21, N (%) | 4570 (41.7) | 1409 (20.5) | 910 (58.6) | 1208 (83.7) | 1043 (96.6) |
| Proportion with FAS score >34, N (%) | 1228 (11.2) | 211 (3.1) | 95 (6.1) | 301 (20.9) | 621 (57.5) |



**Figure F. Pairwise agreement (Cohen's kappa) between symptom clusters (left panel) and conditional probability (right panel) of experiencing symptoms of a specific cluster (columns) given another specific symptom cluster (rows). The overall prevalence of a specific symptom cluster is included in diagonal cells.**

**Table C. Mutually adjusted prevalence ratios with 95% confidence intervals for new symptom clusters**

| | Any | Fatigue | Neurocognitive impairment | Chest symptoms | Smell or taste disorder | Anxiety/ depression | Headache/ dizziness |
|---|---|---|---|---|---|---|---|
| Age, per 10 years | 1.00 (0.99 to 1.01) | **1.04** (1.01 to 1.06) | **1.04** (1.01 to 1.06) | 0.98 (0.96 to 1.00) | **0.94** (0.92 to 0.97) | **1.05** (1.01 to 1.08) | 0.99 (0.96 to 1.02) |
| Sex | | | | | | | |
|   Male (ref.) | | | | | | | |
|   Female | **1.20** (1.16 to 1.24) | **1.27** (1.21 to 1.34) | **1.32** (1.24 to 1.40) | **1.27** (1.19 to 1.35) | **1.25** (1.16 to 1.35) | **1.32** (1.22 to 1.44) | **1.32** (1.21 to 1.44) |
| University entrance qualification | | | | | | | |
|   Yes (ref.) | | | | | | | |
|   No | 1.02 (0.99 to 1.06) | 1.05 (1.00 to 1.11) | 1.02 (0.96 to 1.08) | **1.08** (1.02 to 1.15) | 1.03 (0.96 to 1.11) | 1.03 (0.96 to 1.12) | **1.11** (1.03 to 1.21) |
| Smoking status, N (%) | | | | | | | |
|   Never (ref.) | | | | | | | |
|   Former | **1.07** (1.04 to 1.11) | **1.10** (1.04 to 1.17) | **1.18** (1.11 to 1.25) | **1.14** (1.07 to 1.22) | 1.05 (0.97 to 1.14) | **1.11** (1.02 to 1.21) | **1.14** (1.04 to 1.24) |
|   Current | **1.06** (1.01 to 1.11) | **1.17** (1.08 to 1.26) | **1.11** (1.01 to 1.22) | **1.17** (1.06 to 1.28) | 1.03 (0.92 to 1.16) | **1.22** (1.08 to 1.38) | **1.24** (1.09 to 1.40) |
| BMI, per 5 kg/m² | **1.02** (1.01 to 1.03) | **1.05** (1.03 to 1.07) | **1.04** (1.02 to 1.07) | **1.10** (1.07 to 1.13) | 1.00 (0.96 to 1.03) | 1.02 (0.99 to 1.06) | **1.04** (1.01 to 1.08) |
| Time since positive PCR, per month | 1.00 (0.99 to 1.01) | 1.00 (0.98 to 1.01) | 1.01 (0.99 to 1.03) | 1.00 (0.98 to 1.02) | **1.04** (1.02 to 1.07) | 1.00 (0.98 to 1.03) | 0.99 (0.97 to 1.02) |
| Treatment of acute SARS-CoV-2 infection | | | | | | | |
|   No medical care (ref.) | | | | | | | |
|   Outpatient care | **1.36** (1.33 to 1.40) | **1.79** (1.70 to 1.88) | **1.87** (1.76 to 1.98) | **1.83** (1.72 to 1.95) | **1.33** (1.22 to 1.44) | **2.05** (1.89 to 2.22) | **1.94** (1.78 to 2.11) |
|   Inpatient care | **1.41** (1.34 to 1.48) | **1.89** (1.73 to 2.07) | **1.93** (1.74 to 2.14) | **1.96** (1.75 to 2.18) | **1.23** (1.02 to 1.48) | **2.17** (1.87 to 2.52) | **2.10** (1.79 to 2.46) |
| Pre-existing conditions | | | | | | | |
|   Musculoskeletal disorders | **1.12** (1.09 to 1.16) | **1.17** (1.11 to 1.23) | **1.20** (1.13 to 1.27) | **1.24** (1.16 to 1.32) | **1.22** (1.13 to 1.32) | **1.24** (1.14 to 1.34) | **1.29** (1.18 to 1.40) |
|   Cardiovascular disorders | **1.07** (1.03 to 1.11) | **1.11** (1.04 to 1.18) | 1.04 (0.97 to 1.12) | **1.14** (1.06 to 1.23) | 1.04 (0.94 to 1.15) | 1.05 (0.95 to 1.16) | 1.02 (0.92 to 1.13) |
|   Neurological or sensory disorders | **1.04** (1.01 to 1.08) | 1.05 (0.99 to 1.12) | **1.12** (1.05 to 1.20) | **1.13** (1.05 to 1.21) | 1.06 (0.97 to 1.16) | 1.05 (0.95 to 1.15) | 0.99 (0.89 to 1.09) |
|   Metabolic disorders | **1.05** (1.02 to 1.09) | **1.12** (1.05 to 1.19) | **1.12** (1.05 to 1.20) | **1.09** (1.02 to 1.17) | 1.07 (0.98 to 1.18) | 1.06 (0.96 to 1.16) | **1.13** (1.03 to 1.25) |
|   Mental disorders | **1.10** (1.06 to 1.14) | **1.16** (1.09 to 1.24) | **1.19** (1.11 to 1.28) | **1.11** (1.02 to 1.19) | 1.08 (0.98 to 1.19) | 0.91 (0.81 to 1.01) | **1.17** (1.05 to 1.30) |
|   Respiratory diseases | **1.06** (1.02 to 1.10) | **1.15** (1.08 to 1.22) | **1.12** (1.04 to 1.20) | **1.09** (1.01 to 1.18) | 0.91 (0.82 to 1.01) | 1.04 (0.94 to 1.15) | 1.10 (0.99 to 1.22) |
|   Dermatological diseases | 1.03 (0.99 to 1.08) | 1.01 (0.94 to 1.08) | 1.04 (0.96 to 1.13) | 1.03 (0.95 to 1.12) | 1.07 (0.96 to 1.19) | 1.10 (0.98 to 1.22) | 0.92 (0.82 to 1.04) |
|   Cancer | 1.02 (0.95 to 1.09) | 0.97 (0.86 to 1.10) | 1.03 (0.91 to 1.18) | 0.99 (0.85 to 1.14) | 1.08 (0.91 to 1.30) | 0.87 (0.71 to 1.07) | 0.95 (0.77 to 1.17) |

**Table C. Mutually adjusted prevalence ratios with 95% confidence intervals for new symptom clusters (…continued)**

| | Musculoskeletal pain | Upper respiratory symptoms | Rash/paresthesia | Hair loss | Abdominal symptoms | Nausea/vomiting | Chills/fever |
|---|---|---|---|---|---|---|---|
| Age, per 10 years | **1.20** (1.16 to 1.25) | **1.12** (1.07 to 1.16) | **1.10** (1.04 to 1.15) | 0.97 (0.92 to 1.03) | 1.02 (0.95 to 1.09) | 1.01 (0.92 to 1.10) | 1.07 (0.95 to 1.20) |
| Sex | | | | | | | |
| Male (ref.) | | | | | | | |
| Female | **1.36** (1.24 to 1.49) | **1.14** (1.03 to 1.26) | **1.36** (1.20 to 1.54) | **4.77** (3.86 to 5.90) | **1.35** (1.13 to 1.61) | **2.02** (1.57 to 2.60) | **1.51** (1.13 to 2.01) |
| University entrance qualification | | | | | | | |
| Yes | | | | | | | |
| No | **1.13** (1.03 to 1.24) | **1.17** (1.06 to 1.30) | **0.88** (0.78 to 0.99) | 1.12 (0.97 to 1.30) | 1.17 (0.99 to 1.39) | **1.27** (1.02 to 1.58) | 1.14 (0.86 to 1.51) |
| Smoking status, N (%) | | | | | | | |
| Never (ref.) | | | | | | | |
| Former | 1.07 (0.97 to 1.18) | 0.93 (0.83 to 1.04) | **1.20** (1.05 to 1.37) | 0.99 (0.84 to 1.17) | 1.03 (0.86 to 1.24) | **1.37** (1.09 to 1.73) | 1.25 (0.93 to 1.66) |
| Current | **1.37** (1.20 to 1.56) | **1.28** (1.11 to 1.49) | **1.41** (1.17 to 1.70) | 1.02 (0.81 to 1.30) | 1.08 (0.83 to 1.42) | **1.60** (1.18 to 2.17) | **1.72** (1.17 to 2.51) |
| BMI, per 5 kg/m² | **1.08** (1.04 to 1.12) | **1.09** (1.04 to 1.14) | **1.08** (1.02 to 1.14) | **1.07** (1.01 to 1.13) | 0.98 (0.90 to 1.07) | 0.94 (0.84 to 1.05) | 1.01 (0.89 to 1.14) |
| Time since positive PCR, per month | 0.99 (0.97 to 1.02) | 0.98 (0.95 to 1.01) | 1.01 (0.98 to 1.05) | **0.88** (0.84 to 0.92) | 0.98 (0.93 to 1.03) | 0.96 (0.90 to 1.02) | 0.96 (0.88 to 1.03) |
| Treatment of acute SARS-CoV-2 infection | | | | | | | |
| No medical care (ref.) | | | | | | | |
| Outpatient care | **2.16** (1.97 to 2.37) | **2.07** (1.86 to 2.29) | **2.08** (1.82 to 2.37) | **2.24** (1.93 to 2.61) | **2.41** (2.02 to 2.88) | **2.33** (1.85 to 2.92) | **3.08** (2.33 to 4.06) |
| Inpatient care | **2.17** (1.83 to 2.56) | **1.79** (1.46 to 2.20) | **3.03** (2.45 to 3.74) | **4.06** (3.22 to 5.11) | **2.74** (1.98 to 3.78) | **2.70** (1.76 to 4.14) | **3.42** (2.10 to 5.57) |
| Pre-existing conditions | | | | | | | |
| Musculoskeletal disorders | **1.21** (1.10 to 1.32) | **1.29** (1.16 to 1.43) | 1.13 (0.99 to 1.29) | 1.07 (0.91 to 1.25) | **1.22** (1.02 to 1.46) | 1.23 (0.98 to 1.55) | 1.07 (0.81 to 1.41) |
| Cardiovascular disorders | **1.13** (1.02 to 1.25) | **1.15** (1.02 to 1.29) | 1.02 (0.87 to 1.19) | 1.17 (0.97 to 1.41) | 1.22 (1.00 to 1.49) | 1.01 (0.77 to 1.33) | 1.08 (0.79 to 1.49) |
| Neurological or sensory disorders | 1.10 (0.99 to 1.22) | **1.14** (1.01 to 1.28) | **1.25** (1.08 to 1.44) | 1.02 (0.85 to 1.23) | 1.03 (0.84 to 1.27) | 1.15 (0.89 to 1.47) | 0.88 (0.63 to 1.23) |
| Metabolic disorders | 1.09 (0.98 to 1.21) | 1.07 (0.95 to 1.21) | **1.17** (1.01 to 1.35) | **1.19** (1.01 to 1.41) | 1.19 (0.97 to 1.45) | 1.27 (0.99 to 1.62) | 1.08 (0.79 to 1.47) |
| Mental disorders | **1.18** (1.06 to 1.32) | 1.11 (0.97 to 1.26) | **1.18** (1.01 to 1.38) | 1.09 (0.90 to 1.32) | **1.31** (1.06 to 1.62) | **1.70** (1.33 to 2.18) | 1.21 (0.84 to 1.72) |
| Respiratory diseases | 1.05 (0.94 to 1.18) | **1.17** (1.03 to 1.33) | 1.16 (0.99 to 1.36) | 0.94 (0.76 to 1.14) | 0.99 (0.79 to 1.24) | 1.07 (0.81 to 1.42) | 1.18 (0.83 to 1.66) |
| Dermatological diseases | 0.97 (0.85 to 1.11) | 1.06 (0.92 to 1.22) | 1.17 (0.99 to 1.37) | 1.10 (0.90 to 1.35) | 0.89 (0.69 to 1.15) | 0.95 (0.70 to 1.29) | 1.17 (0.81 to 1.68) |
| Cancer | 1.13 (0.94 to 1.37) | 1.08 (0.86 to 1.34) | 0.81 (0.59 to 1.12) | 0.88 (0.62 to 1.27) | 1.10 (0.75 to 1.61) | 1.05 (0.65 to 1.71) | 1.27 (0.71 to 2.25) |

**Table D. Mutually adjusted prevalence ratios with 95% confidence intervals for new symptom clusters with grade of impairment moderate to strong**

| | Any | Fatigue | Neurocognitive impairment | Chest symptoms | Smell or taste disorder | Anxiety/depression | Headache/ dizziness |
|---|---|---|---|---|---|---|---|
| Age, per 10 years | 1.00 (0.98 to 1.02) | **1.06** (1.02 to 1.09) | **1.05** (1.01 to 1.09) | 0.99 (0.95 to 1.04) | 0.96 (0.92 to 1.00) | 1.03 (0.99 to 1.08) | 0.99 (0.94 to 1.05) |
| Sex | | | | | | | |
| Male (ref.) | | | | | | | |
| Female | **1.37** (1.30 to 1.44) | **1.46** (1.35 to 1.58) | **1.52** (1.37 to 1.68) | **1.33** (1.20 to 1.48) | **1.36** (1.21 to 1.53) | **1.47** (1.30 to 1.66) | **1.49** (1.29 to 1.72) |
| University entrance qualification | | | | | | | |
| Yes (ref.) | | | | | | | |
| No | **1.14** (1.09 to 1.20) | **1.19** (1.10 to 1.28) | **1.09** (0.99 to 1.20) | **1.25** (1.13 to 1.39) | **1.10** (0.99 to 1.23) | **1.15** (1.02 to 1.29) | **1.37** (1.19 to 1.57) |
| Smoking status, N (%) | | | | | | | |
| Never (ref.) | | | | | | | |
| Former | **1.12** (1.06 to 1.17) | **1.12** (1.03 to 1.21) | **1.25** (1.13 to 1.38) | **1.18** (1.06 to 1.31) | 1.07 (0.94 to 1.21) | **1.24** (1.09 to 1.40) | 1.13 (0.97 to 1.31 |
| Current | **1.22** (1.14 to 1.31) | **1.37** (1.24 to 1.53) | **1.26** (1.09 to 1.46) | **1.27** (1.09 to 1.48) | **1.30** (1.11 to 1.54) | **1.49** (1.26 to 1.75) | **1.34** (1.10 to 1.64) |
| BMI, per 5  kg/m² | **1.05** (1.03 to 1.07) | **1.09** (1.05 to 1.12) | **1.06** (1.02 to 1.11) | **1.16** (1.11 to 1.20) | **1.08** (1.02 to 1.13) | 1.04 (0.99 to 1.10) | 1.04 (0.97 to 1.10) |
| Time since positive PCR, per month | 1.00 (0.98 to 1.01) | 0.98 (0.96 to 1.01) | 1.01 (0.98 to 1.03) | 1.01 (0.98 to 1.04) | **1.03** (1.00 to 1.07) | 1.00 (0.96 to 1.03) | 0.97 (0.94 to 1.02) |
| Treatment of acute SARS-CoV-2 infection | | | | | | | |
| No medical care (ref.) | | | | | | | |
| Outpatient care | **1.69** (1.62 to 1.77) | **2.12** (1.97 to 2.28) | **2.27** (2.05 to 2.50) | **2.43** (2.19 to 2.69) | **1.48** (1.31 to 1.68) | **2.50** (2.23 to 2.80) | **2.79** (2.42 to 3.21) |
| Inpatient care | **1.82** (1.68 to 1.97) | **2.18** (1.91 to 2.50) | **2.64** (2.24 to 3.11) | **2.52** (2.10 to 3.02) | 1.29 (0.98 to 1.71) | **2.57** (2.06 to 3.20) | **3.16** (2.46 to 4.05) |
| Pre-existing conditions | | | | | | | |
| Musculoskeletal disorders | **1.19** (1.14 to 1.25) | **1.23** (1.14 to 1.33) | **1.30** (1.18 to 1.43) | **1.32** (1.19 to 1.46) | **1.24** (1.10 to 1.40) | **1.18** (1.04 to 1.33) | **1.34** (1.17 to 1.55) |
| Cardiovascular disorders | **1.11** (1.05 to 1.17) | **1.12** (1.03 to 1.22) | 0.99 (0.88 to 1.11) | **1.12** (1.00 to 1.27) | 0.97 (0.83 to 1.12) | 1.02 (0.88 to 1.18) | 0.92 (0.77 to 1.10) |
| Respiratory diseases | **1.11** (1.05 to 1.18) | **1.20** (1.10 to 1.31) | **1.16** (1.03 to 1.30) | **1.19** (1.05 to 1.35) | 0.93 (0.79 to 1.09) | 1.03 (0.89 to 1.20) | 1.01 (0.84 to 1.21) |
| Mental disorders | **1.20** (1.14 to 1.27) | **1.26** (1.16 to 1.37) | **1.46** (1.31 to 1.63) | **1.17** (1.03 to 1.32) | 1.07 (0.92 to 1.24) | 1.04 (0.89 to 1.21) | **1.38** (1.17 to 1.62) |
| Neurological or sensory disorders | **1.09** (1.03 to 1.15) | **1.15** (1.06 to 1.25) | 1.11 (0.99 to 1.23) | **1.25** (1.12 to 1.40) | 1.11 (0.97 to 1.28) | 1.05 (0.91 to 1.20) | 0.97 (0.82 to 1.15) |
| Dermatological diseases | 1.05 (0.99 to 1.12) | 1.04 (0.94 to 1.15) | 0.97 (0.85 to 1.11) | 1.02 (0.89 to 1.17) | 1.08 (0.92 to 1.27) | 0.93 (0.79 to 1.11) | 0.81 (0.66 to 1.00) |
| Cancer | 0.99 (0.88 to 1.10) | 0.88 (0.73 to 1.05) | 1.01 (0.82 to 1.25) | 0.97 (0.77 to 1.24) | 1.00 (0.75 to 1.33) | 0.94 (0.71 to 1.24) | 0.87 (0.61 to 1.24) |
| Metabolic disorders | 1.04 (0.98 to 1.10) | **1.09** (1.00 to 1.19) | 1.15 (1.03 to 1.28) | 1.09 (0.97 to 1.23) | 1.04 (0.90 to 1.19) | 1.07 (0.94 to 1.23) | 1.03 (0.87 to 1.21) |

**Table D. Mutually adjusted prevalence ratios with 95% confidence intervals for new symptom clusters with grade of impairment moderate to strong (…continued)**

| | Musculoskeletal pain | Upper respiratory symptoms | Rash/paresthesia | Hair loss | Abdominal symptoms | Nausea/vomiting | Chills/fever |
|---|---|---|---|---|---|---|---|
| Age, per 10 years | **1.30** (1.23 to 1.38) | **1.13** (1.04 to 1.22) | **1.12** (1.04 to 1.22) | 0.98 (0.89 to 1.07) | 1.05 (0.93 to 1.18) | 0.99 (0.85 to 1.16) | 1.07 (0.88 to 1.31) |
| Sex | | | | | | | |
| Male (ref.) | | | | | | | |
| Female | **1.55** (1.34 to 1.78) | **1.20** (1.00 to 1.45) | **1.70** (1.38 to 2.10) | **8.32** (5.61 to 12.3) | **1.54** (1.14 to 2.08) | **2.46** (1.55 to 3.89) | 1.67 (0.97 to 2.85) |
| University entrance qualification | | | | | | | |
| Yes (ref.) | | | | | | | |
| No | **1.21** (1.06 to 1.39) | **1.26** (1.04 to 1.52) | 1.04 (0.85 to 1.26) | **1.33** (1.06 to 1.68) | 1.15 (0.87 to 1.52) | 1.13 (0.77 to 1.66) | 1.14 (0.69 to 1.91) |
| Smoking status, N (%) | | | | | | | |
| Never (ref.) | | | | | | | |
| Former | 1.13 (0.98 to 1.30) | 1.07 (0.88 to 1.30) | **1.27** (1.03 to 1.57) | 0.98 (0.76 to 1.26) | 1.07 (0.79 to 1.46) | **1.52** (1.02 to 2.27) | 1.25 (0.75 to 2.10) |
| Current | **1.44** (1.18 to 1.75) | **1.57** (1.21 to 2.04) | **1.69** (1.28 to 2.24) | 1.24 (0.89 to 1.74) | **1.53** (1.03 to 2.27) | **2.14** (1.32 to 3.48) | **1.95** (1.02 to 3.73) |
| BMI, per 5  kg/m² | **1.11** (1.05 to 1.17) | **1.11** (1.02 to 1.20) | 1.08 (0.99 to 1.17) | 1.04 (0.95 to 1.13) | 0.95 (0.81 to 1.11) | 0.80 (0.64 to 1.00) | 0.90 (0.70 to 1.17) |
| Time since positive PCR, per month | 1.00 (0.96 to 1.04) | 0.95 (0.90 to 1.01) | 0.96 (0.91 to 1.02) | 0.87 (0.81 to 0.92) | 1.01 (0.93 to 1.09) | 0.92 (0.83 to 1.02) | 1.03 (0.89 to 1.19) |
| Treatment of acute SARS-CoV-2 infection | | | | | | | |
| No medical care (ref.) | | | | | | | |
| Outpatient care | **2.61** (2.27 to 2.99) | **2.70** (2.23 to 3.27) | **2.55** (2.07 to 3.14) | **2.44** (1.93 to 3.09) | **2.98** (2.22 to 3.99) | **2.65** (1.79 to 3.92) | **3.64** (2.21 to 5.98) |
| Inpatient care | **2.58** (2.03 to 3.30) | **2.55** (1.81 to 3.58) | **4.59** (3.38 to 6.23) | **5.60** (4.01 to 7.82) | **3.90** (2.34 to 6.50) | 2.21 (0.95 to 5.18) | **5.85** (2.75 to 12.4) |
| Pre-existing conditions | | | | | | | |
| Musculoskeletal disorders | **1.21** (1.06 to 1.39) | **1.33** (1.10 to 1.61) | 1.10 (0.89 to 1.35) | 1.08 (0.84 to 1.37) | 1.14 (0.86 to 1.53) | 1.40 (0.95 to 2.05) | 1.28 (0.80 to 2.07) |
| Cardiovascular disorders | **1.18** (1.01 to 1.37) | 1.14 (0.92 to 1.42) | **1.32** (1.04 to 1.67) | 1.32 (1.00 to 1.75) | 1.24 (0.88 to 1.74) | 1.41 (0.86 to 2.32) | 1.13 (0.66 to 1.93) |
| Respiratory diseases | 1.06 (0.90 to 1.26) | **1.60** (1.29 to 1.98) | **1.50** (1.20 to 1.88) | 1.02 (0.75 to 1.37) | 0.97 (0.66 to 1.42) | 1.05 (0.65 to 1.70) | 0.98 (0.52 to 1.86) |
| Mental disorders | **1.29** (1.10 to 1.51) | 1.14 (0.91 to 1.43) | 0.94 (0.73 to 1.21) | 1.02 (0.77 to 1.36) | **1.60** (1.14 to 2.24) | **1.89** (1.24 to 2.89) | 1.07 (0.57 to 2.00) |
| Neurological or sensory disorders | 1.12 (0.96 to 1.30) | 1.11 (0.90 to 1.37) | 1.21 (0.97 to 1.53) | 0.98 (0.75 to 1.30) | 0.93 (0.66 to 1.31) | 1.30 (0.85 to 1.99) | 0.77 (0.42 to 1.42) |
| Dermatological diseases | 0.91 (0.75 to 1.11) | 0.93 (0.72 to 1.22) | 1.07 (0.81 to 1.41) | 1.20 (0.88 to 1.62) | 0.59 (0.36 to 0.97) | 0.44 (0.21 to 0.92) | 0.69 (0.32 to 1.48) |
| Cancer | 0.99 (0.74 to 1.34) | 1.24 (0.85 to 1.82) | 0.82 (0.50 to 1.33) | 0.82 (0.47 to 1.43) | 1.50 (0.85 to 2.64) | 1.47 (0.69 to 3.12) | 1.49 (0.60 to 3.69) |
| Metabolic disorders | 1.03 (0.88 to 1.20) | 0.98 (0.79 to 1.22) | 1.10 (0.87 to 1.38) | **1.32** (1.03 to 1.70) | 1.16 (0.82 to 1.63) | 0.99 (0.62 to 1.59) | 1.25 (0.73 to 2.14) |

Left panel — Attributable percentage loss of general health

| | 18-<30 years | 30-<40 years | 40-<50 years | 50-<60 years | 60-65 years |
|---|---|---|---|---|---|
| Average total loss - men | 6.7 | 7.9 | 10.7 | 11.8 | 13.6 |
| Average total loss - women | 9.4 | 10.5 | 13.4 | 14.3 | 14.8 |
| Unattributed - men | 1.27 | 1.55 | 2.06 | 2.69 | 3.10 |
| Unattributed - women | 1.69 | 1.43 | 1.54 | 2.58 | 2.73 |
| Fatigue - men | 1.51 | 1.78 | 2.84 | 2.65 | 2.99 |
| Fatigue - women | 1.58 | 2.58 | 2.80 | 1.93 | 2.19 |
| Neurocognitive impairment - men | 0.79 | 0.60 | 1.54 | 1.36 | 1.58 |
| Neurocognitive impairment - women | 0.83 | 0.90 | 1.91 | 1.91 | 2.98 |
| Chest symptoms - men | 0.88 | 0.83 | 0.91 | 1.73 | 2.71 |
| Chest symptoms - women | 1.80 | 1.44 | 1.79 | 2.23 | 2.00 |
| Smell or taste disorder - men | 1.01 | 1.06 | 0.92 | 0.52 | 0.63 |
| Smell or taste disorder - women | 1.18 | 1.26 | 1.23 | 1.29 | 0.55 |
| Anxiety/Depression - men | 0.01 | 0.54 | 0.51 | 0.79 | 0.77 |
| Anxiety/Depression - women | 0.68 | 0.25 | 1.05 | 0.78 | 0.94 |
| Headache/dizzyness - men | 0.51 | 0.46 | 0.59 | 0.66 | 0.41 |
| Headache/dizzyness - women | 0.53 | 0.54 | 0.51 | 0.66 | 0.91 |
| Musculoskeletal pain - men | 0.05 | 0.21 | -0.11 | 0.53 | 0.40 |
| Musculoskeletal pain - women | 0.37 | 0.67 | 0.80 | 0.80 | 0.53 |
| Upper respiratory symptoms - men | 0.19 | 0.29 | 0.26 | 0.33 | -0.02 |
| Upper respiratory symptoms - women | 0.07 | 0.14 | 0.14 | 0.74 | 0.57 |
| Rash/paresthesia - men | 0.13 | 0.24 | 0.47 | 0.04 | 0.32 |
| Rash/paresthesia - women | 0.07 | 0.31 | 0.63 | 0.22 | 0.47 |
| Hair loss - men | 0.01 | -0.02 | -0.01 | -0.00 | 0.17 |
| Hair loss - women | -0.03 | 0.48 | 0.08 | 0.13 | 0.37 |
| Abdominal symptoms - men | -0.04 | 0.11 | 0.15 | 0.20 | -0.04 |
| Abdominal symptoms - women | 0.02 | 0.09 | 0.04 | 0.09 | -0.09 |
| Nausea/vomiting - men | 0.22 | 0.03 | 0.08 | 0.06 | 0.34 |
| Nausea/vomiting - women | 0.21 | 0.07 | 0.32 | 0.24 | 0.09 |
| Chills/feverr - men | -0.01 | 0.10 | 0.15 | -0.10 | -0.09 |
| Chills/feverr - women | 0.17 | 0.14 | 0.17 | 0.21 | 0.24 |

Right panel — Attributable percentage loss of working capacity

| | 18-<30 years | 30-<40 years | 40-<50 years | 50-<60 years | 60-65 years |
|---|---|---|---|---|---|
| Average total loss - men | 5.5 | 6.5 | 9.2 | 11.6 | 14.9 |
| Average total loss - women | 7.5 | 9.0 | 12.5 | 14.0 | 15.3 |
| Unattributed - men | 1.02 | 0.61 | 1.25 | 2.47 | 4.13 |
| Unattributed - women | 0.91 | 0.68 | 0.51 | 2.05 | 2.57 |
| Fatigue - men | 1.09 | 1.92 | 3.19 | 2.98 | 3.23 |
| Fatigue - women | 1.52 | 2.55 | 2.70 | 1.92 | 2.41 |
| Neurocognitive impairment - men | 1.16 | 0.88 | 1.51 | 1.56 | 1.73 |
| Neurocognitive impairment - women | 1.42 | 1.67 | 2.78 | 2.39 | 2.69 |
| Chest symptoms - men | 0.37 | 0.62 | 0.21 | 1.20 | 2.12 |
| Chest symptoms - women | 0.52 | 0.68 | 1.17 | 1.37 | 1.75 |
| Smell or taste disorder - men | 0.23 | 0.38 | 0.29 | 0.15 | 0.42 |
| Smell or taste disorder - women | 0.04 | 0.39 | 0.47 | 0.97 | 0.24 |
| Anxiety/Depression - men | 0.16 | 0.45 | 0.83 | 0.83 | 0.45 |
| Anxiety/Depression - women | 1.36 | 0.53 | 1.06 | 0.63 | 1.33 |
| Headache/dizzyness - men | 0.73 | 0.97 | 0.53 | 0.46 | 0.61 |
| Headache/dizzyness - women | 0.41 | 0.59 | 0.61 | 0.83 | 0.82 |
| Musculoskeletal pain - men | 0.07 | 0.06 | -0.02 | 0.90 | 0.79 |
| Musculoskeletal pain - women | 0.37 | 0.45 | 1.14 | 0.72 | 0.47 |
| Upper respiratory symptoms - men | 0.14 | -0.15 | 0.29 | 0.21 | -0.21 |
| Upper respiratory symptoms - women | 0.15 | 0.17 | 0.14 | 1.00 | 0.38 |
| Rash/paresthesia - men | 0.09 | 0.33 | 0.43 | 0.11 | 0.89 |
| Rash/paresthesia - women | 0.14 | 0.38 | 1.02 | 0.32 | 0.64 |
| Hair loss - men | 0.02 | -0.05 | -0.03 | -0.00 | 0.07 |
| Hair loss - women | -0.01 | 0.57 | 0.19 | 0.42 | 0.53 |
| Abdominal symptoms - men | 0.01 | 0.03 | 0.13 | 0.14 | -0.28 |
| Abdominal symptoms - women | 0.21 | 0.07 | 0.12 | 0.30 | 0.01 |
| Nausea/vomiting - men | 0.24 | 0.09 | 0.06 | 0.25 | 0.45 |
| Nausea/vomiting - women | 0.21 | 0.13 | 0.17 | 0.28 | 0.15 |
| Chills/feverr - men | 0.05 | 0.14 | 0.14 | -0.10 | 0.07 |
| Chills/feverr - women | 0.14 | 0.04 | 0.23 | 0.40 | 0.35 |

**Figure G. Attributable percentage loss of general health (left panel) and working capacity (right panel), stratified by age categories and sex.**

**Figure H. Pairwise Pearson`s correlation coefficient between measures of recovered general health, working capacity, physical and mental health score (SF-12), and fatigue assessment.**

**Table E. Participation according to age and sex.**

| Sex | Source population* | Participants (%) |
|---|---|---|
| Male | 24 959 | 4829 (19.3) |
| Female | 25 483 | 6881 (27.0) |
| Total | 50 442 | 11 710 (23.2) |

| Age class (years) | Source population | Participants (%) |
|---|---|---|
| <30 | 14 045 | 2474 (17.6) |
| 30 - <40 | 10 710 | 2158 (20.1) |
| 40 - <50 | 9504 | 2075 (21.8) |
| 50 - <60 | 11 633 | 3443 (29.6) |
| ≥ 60 | 4565 | 1560 (34.2) |
| Total | 50 457 | 11 710 (23.2) |

* n=15 unknown or non-binary sex